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ABSTRACT

ROLES OF 5HT1A RECEPTOR IN CNS NEUROGENESIS
AND ADAM21 IN SPINAL CORD INJURY
Sheila Ann Arnold
July 21, 2011
These studies set out to identify strategies to rescue and repair the adult nervous
system. First, we investigated the role of ciliary neurotrophic factor (CNTF) in SHT1A
receptor-induced neurogenesis in the rodent brain. Systemic treatment with an agonist,
8-0H-DPAT, increased neurogenesis only in rats and not mice, and only in one of the
two neurogenic regions. This increase was not mediated by CNTF. These data suggest
that translation of SHT1A-based studies to human cell replacement therapies should be
reconsidered. Secondly, the role of the plasticity-associated metalloprotease ADAM21
after spinal cord injury was investigated by comparing ADAM21-deficient mice to their
wildtype littermates. No differences in behavioral or histology were found. However, a
comprehensive metalloproteinase gene array revealed that ADAM21 regulates a cluster
of inflammatory genes following injury. This leaves a potential for discovery of specific
pharmaceutical ADAM21 inhibitors to reduce detrimental inflammatory processes
following spinal cord injury.
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CHAPTER ONE
INTRODUCTION
General
Plasticity persist in the adult brain, mainly in two distinct regions known as the
subventricular zone (SVZ) and the subgranular zone (SGZ). With the discovery of
neural stem cells in the adult brain, the concept of neuronal replacement via engraftment
of these cells into the damaged region has sparked excitement. However, in light of
problems faced with engraftment (tumor growth, misguidance, cell death, cognitive
impairment, and lack of sufficient functional recovery), many scientists have refocused
their attention to neuroprotection in order to prevent the initial loss of neurons and
regeneration using the endogenous cells to alter the neurogenic potential. The focus for
regeneration in many neurodegenerative diseases stem from the idea that the newly
born neurons in the SVZ and SGZ could replace the lost neuronal population under the
correct conditions or in a special environment. Aside from prevention of the initial injury
in spinal cord injury, there is a small window of opportunity for limited neuroprotection of
the neurons that were spared in the initial injury. Secondary injury, which is caused by
inflammation in response to the initial injury, causes further damage that could
potentially be prevented thus neuroprotective. However, plasticity also occurs following
spinal cord injury that could have the potential to either cause regeneration of the
damaged or restore function to lost/damaged axons or it can cause increases in pain
perception. This introduction will review topics about CNS neurogenesis,
neurodegenerative diseases, the possible link between 5HT1A receptor induced
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neurogenesis and CNTF. Additionally, there will be a brief introduction to spinal cord
injury, the Metzincin superfamily, matrix metalloproteinases, ADAMs and the possible
role in plasticity ADAM21 could have following spinal cord injury.
Neurogenesis Hypothesis

~cAMP ¢

~CNTF¢

~~~~~~~
Neurogenesis

8-0H-OPAT
~~
~

~~
~

Neurogenesis
The thought that the brain is malleable or able to change is a relatively modern
idea. Though proposed in 1890 by William James in The Principles of Psychology, proof
of neurogenesis was not shown until Smart in 1961 found new neurons in the
subependymal layer of mice. Altman and Das similarly found new neurons in the
hippocampus of rats and showed dividing cells of not only glial origin but also
proliferation of new neurons which continued throughout life in post-natal mammals
refuting the dogma that neurogenesis ceased upon maturation (Smart, 1961, Altman and
Das, 1965). Although these two papers are most commonly cited as being the first to
discover neurogenesis in the adult brain, Smart references papers written by Opalski in
1934 and Kuhlenbeck in 1944 as referring to "the subependymal cell plate ... a potential
source of undifferentiated cells which may on occasion give rise to neoplasms."
However, the idea of adult neurogenesis was still controversial even after other
laboratories had replicated this phenomenon (Hinds, 1968b, a, Kaplan and Hinds, 1977).
Eventually, it became accepted that new neurons are continually added to the brain
circuitry throughout life. Neurogenesis in the adult mammalian brain is now widely
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known to occur in two distinct and unique regions of the brain-the lateral wall of the
ventricles, known as the subventricular zone (SVZ), and in the sub granular zone (SVZ)
of the dente gyrus in the hippocampal formation (Smart, 1961, Altman and Das, 1966,
Altman, 1969, Lois and Alvarez-Buylla, 1994, Eriksson et aI., 1998, Goldman, 1998,
Gage, 2000, Alvarez-Buylla and Lim, 2004, Hoglinger et aI., 2004, Lie et aI., 2004, Sanai
et aI., 2004, Ming and Song, 2005, Hagg, 2009, Kriegstein and Alvarez-Buylla, 2009,
Suh et aI., 2009, Ma et aI., 2010, Soumier et aI., 2010). In non-human primates,
neurogenesis in the SGZ of the hippocampal formation of marmoset monkeys was found
to be decreased with stress as was shown in other animals like the tree shrew and rat
(Gould et aI., 1997, Gould et aI., 1998). Although neurogenesis was found in the SVZ
and SGZ in some animals, the absence of neurogenesis in the adult human was still
central dogma until relatively recent years. Now it is known that neurogenesis does
occur in humans as was shown in the postmortem hippocampal formation of the brain in
adult human cancer patients that received BrdU as a way to track the proliferation rate of
their cancer (Eriksson et aI., 1998). However, there are conflicting reports of the
presence or lack thereof of a rostral migratory stream in humans (Bedard and Parent,
2004, Sanai et aI., 2004, Curtis et aI., 2007b, Sanai et aI., 2007).
In the SVZ, there has been controversy over what cell type is the neural stem
cell. A report published in 1999 indicated that ependymal cells were responsible for the
generation of new neurons which migrate to the olfactory bulb (Johansson et aI., 1999).
However, shortly thereafter, a study was published showing data in support of type B
cells (SVZ astrocytes) and not ependymal cells are the cell type of origin of the neural
stem cells in the SVZ (Doetsch et aI., 1999). These type B cells give rise to both type A
(migrating neuroblasts) and type C (precursor cells). The concept of the SVZ astrocytes
is the more widely accepted explanation for the origin of the neural stem cells in the
SVZ; however, this controversy has yet to be fully resolved since there is a possibility
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that these two populations in question are one and the same (Chojnacki et aI., 2009).
Likewise, in the hippocampal formation there are type 1 and type 2 which are similar to
the type B and type C cell, respectively, in the SVZ (Zhao et aI., 2008, Suh et aI., 2009).
Both type B and type 1 cells resemble radial glial cells found in development. The
finding that astrocytes are the neural stem cells responsible for the neurogenesis in the
SVZ and SGZ means that in cases of neurodegenerative diseases, the astrocytes which
are spared can possibly be exploited in order to replace neurons that are being lost.
In rodents, the majority of adult neurogenesis occurs in the SVZ at a rate of
approximately 10 times more than in the SGZ (Lois and Alvarez-Buylla, 1994, Cameron
and Mckay, 2001, Winner et aI., 2002, Rao and Shetty, 2004, Abrous et aI., 2005). The
newly born neuroblasts migrate from the SVZ along the rostral migratory stream to the
olfactory bulb (OB) and from the SGZ into the neighboring granule cell layer,
respectively, where they either become integrated as neurons or die (Cameron et aI.,
1993, Luskin, 1993, Lois and Alvarez-Buylla, 1994, Morshead et aI., 1998, Gould et aI.,
1999, Hastings and Gould, 1999, Dayer et aI., 2003). The new neurons from the SVZ
migrate to the olfactory bulb become 90% GABAergic and 10% dopaminergic neurons
while the new neurons in the SGZ become excitatory glutamatergic granule neurons
(Knobloch and Jessberger, 2011).

Neurodegenerative diseases
Neurogenesis creates and sustains hope for people who have
neurodegenerative diseases such as Huntington's disease, Parkinson's disease, ALS,
etc. Although these diseases are different in their origination/development, they all
share a common characteristic-loss of neurons. The neuronal population that is lost is
different in these diseases. If the endogenous neurogenesis can be directed or focus on
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replenishment of neurons lost over the progression of the disease then maybe we can
attenuate the progression or quite possibly find a treatment/cure for these diseases.
However, first the biology of neurogenesis and its endogenous regulation must first be
explored before we can pharmacologically manipulate it in various disease states as
opposed to engraftment of neural stem cells. Pharmaceutical intervention has less
ethical and safety hurdles to overcome before it can be utilized in neurodegenerative
diseases. There is a multitude of safety and ethical concerns with grafting neural stem
cells some of which are cognitive impairment, tumor development, migration to
unintended areas, undesirable differentiation, and genetic and epigenetic changes in the
cell population (Mathews et aL, 2008). In about 15% of Parkinson's patients, neural
transplantation induced dyskinesia and over time cells inside the neural engraftment
take on the pathology of Parkinson's disease (Brundin et aL, 2010, Lane et aL, 2010).
Most concerning is the possibility of the donor cells developing into tumors as was the
case with a boy who receive intrathecal and intracerebral injection of fetal human neural
stem cells and later developed a donor-derived brain tumor (Amariglio et aL, 2009). For
these reasons, many scientists have switched their focus from engraftment to stimulation
of endogenous targets that promote neurogenesis which now appears to be a more
practical approach in light of the growing controversies involving engraftment in humans
or human-non-human primates engraftments (Greene et aL, 2005, Mathews et aI.,
2008).

Ciliary Neurotrophic Factor
Many endogenous molecules have been found to regulate adult CNS
neurogenesis (Lie et aL, 2004, Hagg, 2005, Ming and Song, 2005, Hagg, 2009, Suh et
aL, 2009, Bath and Lee, 2010). Endogenous ciliary neurotrophic factor (CNTF) is
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responsible for approximately 30% of neurogenesis in the SVZ as shown in CNTF-/mice and by blocking CNTF antibody injections (Emsley and Hagg, 2003, Yang et aI.,
2008). We have focused our attention on CNTF because it is produced almost
exclusively in the nervous system (Stockli et aI., 1989, Ip, 1998) and would therefore be
a good target for indirect stimulation of neurogenesis by administration of systemic small
molecule drugs. By indirectly stimulating CNTF in the specific environment in which we
wish to induce a neurogenic response, we can avoid issues with low CNS bioavailability
and undesirable side effects associated with systemically delivered CNTF such as fever,
fatigue, and weight loss (Miller et aI., 1996, Thoenen and Sendtner, 2002). In culture,
CNTF drives precursor cells to differentiate into astrocytes (Bonni et aI., 1997).
However, an intraventricular injection of CNTF increased proliferation in the SVZ, but did
not seem to affect the normal neuronal cell fate (Emsley and Hagg, 2003). Thus, CNTF
may be a good target for indirect stimulation to make more new neurons in the adult
CNS.
Previously, we have shown that dopamine from the nigrostriatal projections
induce neurogenesis via 02 receptors and that this is entirely mediated by astroglial
CNTF (Baker et aI., 2004, Yang et aI., 2008). This is consistent with the fact that 02
receptors inhibit cAMP (Vallar and Meldolesi, 1989, Kalkman et aI., 2003), whereas
CNTF is under negative regulation by cAMP in astrocytes (Carroll et aI., 1993, Rudge et
aI., 1994). Astrocytes are our target instead of neurons because the astrocytes are
spared in neurodegenerative diseases whereas the neurons are dead, dying or
dysfunctional therefore they would not be a good target for neuroregeneration. With
further research, the astrocytes can be pharmacologically induced to become a factory
for endogenous production of various factors such as CNTF. In order to decrease
systemic side effects of the drugs used to stimulate the 02 receptor, a low dose
combination with a similar acting drug might be more beneficial.
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Serotonin
The serotonin receptors, 5-hydroxytryptamin receptor or 5HT receptors are a
group of G coupled protein receptors (excitatory and inhibitory) with the exception of
5HT3 which is a ligand-gated Na+ and K + cation channel (Maricq et aI., 1991).
Serotonin receptors include 7 different families 1,2, 3, 4, 5, 6, and 7 with subtypes
signified with a, b, c, etc. (Hoyer et aI., 2002, Savitz et aI., 2009). 5HT receptors have a
wide array of functions ranging from modulation of mood (anxiety and depression),
cognition, learning, memory, aggression, appetite, migraines, REM sleep, pain
processing, and release of a number of neurotransmitters and hormones. 5HT
receptors, in the periphery, facilitate smooth muscle contraction, platelet aggregation,
gastrointestinal function, and impact upon pain processing. The 5HT1 receptor family is
characterized as a seven transmembrane domain receptor which upon activation,
couples to regulatory G proteins that negatively regulates/inhibit adenylyl cyclase (AC)
resulting in a decrease of cAMP (Mendez et aI., 1999, Azmitia, 2001, Kalkman et aI.,
2003, Vanhoose et aI., 2004). We would expect this decreased cAMP to increase CNTF
as we have seen with the 02 receptor leading to an increase in neurogenesis (Yang et
al.,2008).
Of this family, we have chosen to pursue serotonin receptor 5HT1A because of
its regulatory role in decreasing cAMP and its location in the two neurogenic niches of
the brain. When most people talk about the 5HT1A receptor they are referring to the
neuronal 5HT1A receptor; however, the 5HT1A receptors were also found to be
expressed on subset of GFAP+ cells in the lateral septal nucleus and the polymorphic
layer of the OG (Whitaker-Azmitia et aI., 1993). In addition to astrocytes with 5HT1A
receptors, neuronal 5HT1A is found in the serotonergic projections from the raphe nuclei
to the SVZ overlap with dopaminergic fibers in the SVZ where neurogenesis occurs and
where a high expression of CNTF is found; likewise, in the hippocampus, neuronal
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5HT1A is located in the soma and dendrites of large interneurons (Azmitia et aI., 1992).
It is important to know the location and type of neuronal 5HT1A receptor since the
autoreceptors found in the serotonergic projections from the raphe nuclei to the SVZ
have the potential to inhibit or "put the brakes on" serotonin induced activity and their
regulation can be affected by 5HT1A agonist; however, the 5HT1A receptors in the
hippocampal formation are not affected by agonist treatment as they are heteroreceptors
(Riad et aI., 2001). Interestingly, 5HT1A receptor is found in highest abundance in
astrocytes in the two regions of the brain where neurogenesis occurs throughout life.
The 5HT1 A receptor is found in ninety percent of the astrocytes that are located in the
lateral septa which is adjacent to the subventricular zone; however the greatest
abundance of the 5HT1A receptor is in the polymorphic layer or hilus of the DG
(Whitaker-Azmitia et aI., 1993).

Pharmacological stimulation of serotonin receptors and neurogenesis
Depression is thought to cause a decrease in neurogenesis or vice versa, but the
exact link between these two is still unclear (Kempermann et aI., 2008, Thomas and
Peterson, 2008). Furthermore, neurogenesis as an indicator for effective antidepressant
activity of serotonin is still under debate. In 129Sv/Ev mice, the antidepressant effects of
Fluoxetine was seen to increase neurogenesis; however, within the same lab this finding
could not be replicated with BALB/cJ mice (Santarelli et aI., 2003, Holick et aI., 2008) or
BALB/cJ and C57BLl6J mice in another laboratory (Navailles et aI., 2008).
Serotonin or activation of the serotonin receptor has been shown to increase
neurogenesis in both the SVZ and SGZ in adult rats (Brezun and Daszuta, 1999, Brezun
and Daszuta, 2000, Banasr et aI., 2004, Daszuta et aI., 2005, Huang and Herbert, 2005,
Zhang et aI., 2009, Soumier et aI., 2010). Additionally, a landmark study (Santarelli et
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aI., 2003) showed hippocampal neurogenesis in adult mice, and the effects of
antidepressants, are regulated specifically through the 5HT1A receptor, using 5HT1A-/mice and 8-0H-DPAT, which is a selective agonist for the 5HT1A receptor (Middlemiss
and Fozard, 1983). In Chapter 2, our studies into the role of serotonin 1a agonist, 8-0HDPAT, in regulating CNTF and adult neurogenesis in the SVZ and SGZ of mice and rats
will be discussed.

Spinal Cord Injury
Spinal cord injury begins with the shear mechanical injury which causes tissue
damage, i.e., neuronal and glial death, damage to axons, and destruction of blood
vessels at the injury site. The initial insult is just the beginning of the pathology that
ensues afterwards. Subsequently, a secondary injury occurs due to inflammation in
response to the tissue damage. This inflammation has been shown to have both
detrimental and beneficial properties (Donnelly and Popovich, 2008, Kigerl et aI., 2009).
This inflammation can continue chronically after injury (Fleming et aI., 2006). Within two
weeks a glial scarring begins to form around the epicenter isolating it from the healthier
tissue (Berry et aI., 1983).
The initial inflammatory response begins within an hour of the primary injury as
indicated by a massive rise in TNFa mRNA (Harrington et aI., 2005) along with IL-6 and
IL-1 ~ mRNA (Donnelly and Popovich, 2008). Furthermore, in mice, astrocytes are
thought to be responsible for the initiation of the inflammatory response (Pineau et aI.,
2010). It is these glial cells that can release cytokines such as TNFa, a key player in the
synaptic plasticity, inflammatory pain, and allodynia (Peng et aI., 2006, Zhang et aI.,
2011 b). Several ADAMs (a disintegrin and metalloproteinase) such as ADAM 10,
ADAM17 (aka TACE), and ADAM19 are known to be involved in the ectodomain

9

shedding of TNFa (Hooper et aI., 2005). MMP9 (matrix metalloproteinase 9) plays a
detrimental role and a general metalloproteinase inhibitor greatly improve outcomes
following spinal cord injury (Noble et aI., 2002). Metalloproteinases are central
regulators of tissue remodeling, inflammation, plasticity, and signal transduction. In the
CNS, metalloproteinases have implications in a vast array of diseases to include
cerebral ischemia, spinal cord injury, multiple sclerosis, epilepsy, neuropsychiatric
disorders, and neurodegenerative disorders (Rivera et aI., 2010). Although some
studies have been done on a select few metalloproteinases, they are highly under
studied in the CNS, particularly, the ADAMs family. Therefore, they make a great topic
for further investigation.

Wildtype

ADAM21 Hypothesis

[--:> I

Pain and/or Sprouting

I

ADAM21 deficient

[+!ain and/or Sprouting

I

The Metzincin Superfamily
The metzincin superfamily is comprised of several families, two of which are the
Matrixins and Adamalysin families (Bode et aI., 1993, Gomis-Ruth, 2009). The
metzincin superfamily consists of multi-domain proteins that are named for the
conserved Methionine in the zinc dependent catalytiC site of the metalloproteinase which
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contains an extended zinc binding motif (HEXXHXXGXXH) followed by the highly
conserved "Met-turn" (a 1,4-I3-turn found directly below the zinc binding site which
contains Methionine in the 3 position) (Bode et aI., 1993, Stocker and Bode, 1995,
Stocker et aI., 1995, Gomis-Ruth, 2009, Tallant et aI., 2010). There are four
endogenous inhibitors of metalloproteinases, tissue inhibitors of metalloproteinases
(TIMP1-4), which can modulate the activity of the metalloproteinases (Brew and Nagase,
2010). The Matrixin family is comprised of several subfamilies of matrix
metalloproteinases (MMPs) which include collagenases, gelatinases, membrane-type
MMP, stromelysins, matrilysons, enamelysins, metalloelastases and others (Vu and
Werb, 2000). The Adamalysin family is comprised four subfamilies: ADAM proteins (a
disintegrin and metalloproteinase), ADAMTS proteins (a disintegrin and
metalloproteinase with thrombospondin motif), ADAMTSL proteins (with
thrombospondin-like motif), and SVMP proteins (snake venom metalloproteinase)
(Stocker et aI., 1995, Rivera et aI., 2010).

ADAM proteins
The ADAM proteins contain a prodomain, metalloproteinase domain, disintegrin
domain, cysteine rich region, EGF-like repeat, transmembrane domain, and cytoplasmic
tail (Wolfsberg et aI., 1995, Yang et aI., 2006, Edwards et aI., 2008, Klein and Bischoff,
2011). The ADAMs are most widely known for their sheddase activity which cleaves off
the ectodomain of a membrane bound protein and releasing it into the extracellular
space. The ADAMS family includes a group of enzymes known as a-secretases that
cleave amyloid precursor protein. It has been suggested that ADAM9, ADAM10, and
ADAM17 may form a complex that is associated with decreases of amyloid
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(AI3), thus reducing plaque formation in the normal brain (Asai et aI., 2003, Postina et aI.,
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2004). Ectodomain shedding by ADAMs and other sheddases is used for releasing
signaling molecules, cell adhesion molecules, receptors, and cleavage of other
extracellular proteins (Hooper et aL, 2005) This gives ADAMs the ability to regulate
gene transcription, signaling and cellular adhesion. ADAM17 was the first ADAM in
which a substrate was found and has since been the main focus among ADAMs due to
its sheddase activity on TNFa (Black et aL, 1997, Moss et aL, 1997). Following spinal
cord injury, TNFa is increased within an hour whereas TNFR1 does not increase in the
spinal fluid until 3 to 6 hours after initial insult (Harrington et aL, 2005). TNFa induces
expression of ADAM8 which cleaves TNFa receptor 1 (TNFR1), TNFR1 irreversibly
binds free TNFa resulting in feedback inhibition (Bartsch et aL, 2010). Our lab has
shown ADAM8 expression to increase in endothelial cells and be involved in
angiogenesis following spinal cord injury (Mahoney et aL, 2009). A substrate of
ADAM 10 is fractal kine (CX3CL 1), a chemokine that induces inflammation and leukocyte
migration (Hundhausen et aL, 2007); it can be released from neurons to contribute to the
pain pathway as shown by intrathecal injection of fractalkine resulting in thermal and
mechanical allodynia (Milligan et aL, 2004, Milligan et aL, 2005). This substrate is
common between ADAM10 and ADAM17; however, ADAM10 has constitutive activity
towards fractalkine whereas ADAM17's activity is inducible (Garton et aL, 2001). After
spinal cord injury the metalloproteinase domain of ADAMs can playa diverse role in the
regulation of many processes including inflammation and pain development.
The metalloproteinase domain of ADAM proteins is confined by the pro-domain
containing a cysteine switch rendering it inactive until cleavage of the prodomain occurs.
ADAM8 and ADAM28 have been shown to have autocatalytic activity, removing the
prodomain without the aid of another protein (Howard et aL, 2000, Schlomann et aL,
2002). In humans, several ADAMs, ADAM2, ADAM11, ADAM18, ADAM22, ADAM23,
and ADAM32, are predicted to have an inactive metalloprotease domain due to the
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absence of a the Zn-binding motif seen in other ADAMs (Andreini et aL, 2005, Hooper et
aL, 2005) which would suggest that in those ADAMs, the primary function of the protein
would most likely involve cell-cell or cell-matrix interaction via integrins binding to the
disintegrin domain.
Next to the metalloproteinase domain, ADAMs contain a characteristic disintegrin
domain found only in snake venom metalloproteinases (SVMP) and ADAMs. The
disintegrin domain was first found in SVMP; the disintegrin domain binds integrins on
platelets in order to prevent (thus, dis-integrin) fibrinogen binding resulting in
anticoagulant properties (Gould et aL, 1990).This type of domain is unique in
transmembrane proteins due to the combination with the metalloproteinase and the
disintegrin loop. The disintegrin loop found in ADAMs and PIli SVMP have a distinctive
alignment of the cysteine residues linked by disulfide bonds (Gould et aL, 1990, Calvete
et aI., 2003, Hooper et aL, 2005). With the exception of ADAM15, none of the ADAMs
contain a traditional RGD ligand binding site in the disintegrin domain (Kratzschmar et
aI., 1996), but the disintegrin loop structure (canonical disintegrin loop motif;
CRXXXXXCDXXEXC) containing alternative integrin binding sequence (mostly ECD or
XCD ) are also capable of integrin binding (Bigler et aI., 2000, Zhu et aL, 2000, Evans,
2001, Hooper et aL, 2005, Lu et aL, 2007).
As mentioned above, ADAM8 is present in endothelial cells and thought to be
involved in angiogenesis following spinal cord injury, but whether the metalloproteinase
or the disintegrin domain is involved in the angiogenic response is not yet clear
(Mahoney et aL, 2009). After an injury to the brain, a beta3-containing integrin found on
astrocytes binds to Thy-1 resulting in conversion of astrocytes into reactive astrocytes
(Avalos et aL, 2004). Additionally, ADAM8 and ADAM33 have been associated with the
inflammatory asthma although the mechanism of action is not clear (King et aL, 2004,
Haitchi et aI., 2005, Jie et aL, 2009, Koller et aL, 2009). If we could elucidate the
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mechanism by which these molecules participate in the disease process, we could apply
that knowledge to other system as well. Moreover, the unique combinations of these
various domains make ADAMs a particularly good target for therapeutic drug
intervention. Currently, selectivity of metalloproteinase inhibitors is a problem with the
high degree of homology at the catalytic site (Fisher and Mobashery, 2006, Corbitt et aI.,
2007, Jacobsen et aI., 2010). However, some degree of selectivity was achieve with
GI254023X which inhibits ADAM 17 and ADAM 10, but is preferential to the constitutive
activity of cleavage of fractalkine by ADAM10 (Ludwig et aI., 2005) For the disintegrin,
small peptides that mimic the disintegrin loop can be used as a competitive antagonist
similar to the study with a small peptide resembling the ADAM8 disintegrin binding
domain which resulted in enhanced protection of experimentally induced autoimmune
diseases (Schluesener, 1998). Therefore, drug development against the
metalloproteinase and/disintegrin domain holds promise for later clinical use.

Metalloproteinases in Spinal cord injury
Spinal cord injury has not been widely investigated in terms of ADAM protein
involvement. Apart from expression data, the literature on ADAM proteins following a
spinal cord injury thus far is limited to our lab's finding that ADAM8 has a potential role in
angiogenesis with selective up-regulation localized in the endothelial cells of blood
vessels following spinal cord injury (Mahoney et aI., 2009). In an unpublished
subsequent study, we found no overt phenotype following a contusive spinal cord injury
in ADAM8 deficient mice. Unlike ADAMs, a few MMPs have been found to playa
significant role in resulting pathology after a spinal cord injury (Zhang et aI., 2011 a). For
example, MMP9 has been found to be up regulated after spinal cord injury within 24
hours after spinal cord injury and deletion of MMP9 lead to an increase in functional
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recovery and reduced inflammation due to a reduced barrier disruption (de Castro et aI.,
2000, Noble et aI., 2002). Whereas, MMP2 expression was delayed compared to MMP9
expression and did not increase until day 5 and in MMP2 deficient mice there was an
compensatory increase in MMP9, decreased white matter sparing, impaired functional
recovery and increased reactive astrogliosis (de Castro et aI., 2000, Hsu et aI., 2006).
MMP9 and MMP2 give an example of how a metalloproteinase can be deleterious or
beneficial. Due to the similarities in the metalloproteinase domains of MMPs and
ADAMs, we can hypothesize that the metalloproteinase activity of any ADAM would
have a potential beneficial and/or detrimental role in the pathological events following
spinal cord injury. ADAM21 contains a catalytically active metalloproteinase (Hooft van
Huijsduijnen, 1998) and is found to be present in highly plastic regions in the developing
and adult brain such radial glia lineage cells in the neurogenic niche of the subventricular
zone and in new primary olfactory neurons and their growing axons (Yang et aI., 2005).
After spinal cord injury there is a shift in the balance of excitatory and inhibitory
innervation due to the damage or death to the neurons. In addition, as the inflammatory
processes begin astrocytes increase and can become reactive releasing excess
modulatory factors. This can exacerbate the balance of excitatory and inhibitory signals
leading to sprouting of pain fiber into the area of the spinal cord responsible for
responses to non-noxious stimuli (Kuner, 2010). Since ADAM21 is present where
noxious pain fibers reside in the dorsal horn of the spinal cord, they are likely to be
involved in the inflammation or plasticity that results after insult to the spinal cord. The
localization of ADAM21 in the adult CNS leads to the possibility that ADAM21 has a role
in coordinating the repair/migration processes that follow spinal cord injury. Therefore,
inhibition of ADAM21 could be important to preventing chronic pain or inflammation after
spinal cord injury.
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In the study in Chapter 3, we have used ADAM21-deficient mice to examine the
role of ADAM21 following a contusive spinal cord injury in locomotion, balance, thermal
nociception, as well as histological outcomes: spared white matter, CGRP and GFAP at
the epicenter and the penumbra. In Chapter 4, we investigated the possible
compensation of other metalloproteinases and the regulatory role of ADAM21 following
spinal cord injury in ADAM21-deficient mice. Chapter 5 discusses the implications of the
findings from Chapter 2, 3, and 4 and their potential implications to humans.
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CHAPTER TWO
SEROTONIN 1A RECEPTOR INCREASES SPECIES- AND REGION-SELECTIVE
ADULT CNS NEUROGENESIS, BUT NOT THROUGH CNTF
INTRODUCTION
Neurogenesis in the adult mammalian brain occurs predominantly in the SVZ of
the lateral ventricles and the SGZ of the hippocampal dentate gyrus (Ming and Song,
2005, Hagg, 2009, Kriegstein and Alvarez-Buylla, 2009, Suh et aI., 2009, Soumier et aI.,
2010). SVZ neuroblasts migrate along the rostral migratory stream to the olfactory bulb
and SGZ neuroblasts migrate into the neighboring granule cell layer where they become
integrated neurons or die (Luskin, 1993, Lois and Alvarez-Buylla, 1994, Winner et aI.,
2002).
Many endogenous molecules regulate adult CNS neurogenesis (Lie et aI., 2004,
Hagg, 2005, Ming and Song, 2005, Hagg, 2009, Suh et aI., 2009, Bath and Lee, 2010).
CNTF is responsible for -30% of SVZ neurogenesis as shown in CNTF-/- mice and by
antibody injections (Emsley and Hagg, 2003, Yang et aI., 2008). We study CNTF
because it is produced almost exclusively in the nervous system (Stockli et aI., 1989, Ip,
1998) and would therefore be a good target for indirect stimulation of neurogenesis by
systemic small molecule drugs. We found that nigrostriatal projections induce
neurogenesis via D2 dopamine receptors which is entirely mediated by astroglial CNTF
(Baker et aI., 2004, Yang et aI., 2008). This is consistent with the fact that D2 receptors
inhibit cAMP in astrocytes (Vallar and Meldolesi, 1989, Kalkman et aI., 2003), whereas
CNTF expression is inhibited by cAMP in astrocytes (Carroll et aI., 1993, Rudge et aI.,

17

1994). CNTF is predominately produced by astrocytes (Sendtner et aI., 1994, Oallner et
aI., 2002) which are spared in most neurodegenerative diseases. Therefore, they are
ideal pharmacological targets to serve as CNTF "factories" to enhance endogenous
neurogenesis. This would also circumvent the peripheral side effects and low
bioavailability seen with systemic administration of CNTF (Thoenen and Sendtner,
2002).
We wanted to find additional cAMP-inhibiting drugs to increase CNTF, as they
could be combined with low doses of 02 agonists to reduce systemic drug doses and,
consequently, side effects. 5HT1A is expressed on a subset of astroglia throughout the
brain, in addition to neurons in the raphe nuclei (Whitaker-Azmitia et aI., 1993). Their
activation decreases cAMP levels (Mendez et aI., 1999, Azmitia, 2001, Kalkman et aI.,
2003, Vanhoose et aI., 2004). Colocalization of 5HT1A and GFAP is among the highest
in the polymorphic layer of the dentate gyrus (Whitaker-Azmitia et aI., 1993).
Interestingly, serotonergic and dopaminergic projections to the SVZ overlap where
neurogenesis and high expression of CNTF are located (Hagg, 2005). Activation of
5HT1A increases neurogenesis in the SVZ and SGZ in rats (Brezun and Oaszuta, 1999,
Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). A landmark study
(Santarelli et aI., 2003) showed that hippocampal neurogenesis in 129SvEv mice and
the effects of antidepressants are regulated through 5HT1A, using 5HT1A-/- mice and 8OH-OPAT. Acute but not chronic 8-0H-OPAT treatment increases SGZ proliferation in
C57BLl6J mice (Klempin et aI., 2010). Here, we tested whether CNTF mediates the
neurogenic effects of 8-0H-OPAT in the SVZ and SGZ of adult C57BLl6J and 129SvEv
mice, as compared to rats.
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MATERIAL AND METHODS
Animals
A total of 116 mice were used, Le., 64 CS7BLl6J adult male mice (8-12 wks, 2030g, stock # 000664, Jackson Laboratory, Bar Harbor, ME, USA), 40 129SvEv adult
male mice (model # 129SVE-M [129S6/SvEvTac], 11 wks, 20-30 g, Taconic, Hudson,
NY, USA), and 12 wild type background of our CNTF mice (essentially CS7BLl6) were
used. In addition, 10 adult male Sprague-Dawley rats (280-3S0g, Harlan, Indianapolis,
IN) were used. The average weight of the animals in each experimental group was the
same. All invasive procedures in mice were performed under deep anesthesia obtained
by an intraperitoneal injection of 0.4 mg/g body weight Avertin (2,2,2-tribromoethanol in
0.02 ml of 1.2S% 2-methyl-2-butanol in saline, Sigma-Aldrich, St Louis, MO, USA). Rats
were anesthetized with an intramuscular injection of a mixture (62.S !Jg/g weight of the
animal) containing S ml of ketamine (SOO mg/ml, Hospira, Lake Forest, IL), O.S ml of
acepromazine (10 mg/ml, ButlerSchein, Dublin, OH), and 1.2 ml xylazine (20 mg/ml,
Akorn, Decantur, IL) diluted in 13.3 ml of 0.9% saline. All animal procedures were
performed according to University of Louisville Institutional Animal Care and Use
Committee protocols and the National Institutes of Health guidelines.

5HT1A agonist treatment and BrdU injection protocols
The animals were given saline or (R)-(+)-8-Hydroxy-DPAT dissolved in saline (1
mg/kg/day, Cat # H-140; Sigma-Aldrich, St. Louis, MO), a full and specific SHT1A
agonist and active enantiomer of (±)-8-hydroxy-DPAT. It was administered either Lp.
once daily for 3 days or s.c. via Alzet pump (Cat # 10030 with a flow rate of 1 !JI/day for
3 days, or Cat # 1002 with a flow rate of 0.2S !JI/day for 14 days or Cat #: 1004 with a
flow rate of 0.11 !JI/day for 28 days; Durect Corp., Cupertino, CA). The 14 day pumps
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were replace on day 14 with a new 14-day pump with fresh reagent for the 28-day
infusion in C57BLl6J mice. 5-Bromo-2'-deoxyuridine (BrdU; Cat #: B5002, SigmaAldrich, St. Louis, MO) was injected at 50 mglkg twice daily for 3 days with the final
injection 2 hrs before processing for histology.

mRNA measurements by quantitative real-time reverse transcription-PCR (qPCR)
To obtain total RNA, each sample was isolated from freshly dissected 0.5 mm
wide SVZ strips or the entire hippocampal formation, flash frozen using liquid nitrogen,
and isolated from a commercial kit (Cat #: 74104, Qiagen, Valencia, CA). Briefly, 1 I..Ig
RNA was ONAsed (Cat #: 18068-015, Invitrogen, Carlsbad, CA) and used as templates
for reverse transcription, which included 1 1..11 of a 0.5 1..1 gl 1..1 I random primers (Cat# :
C1181,Promega, Madison, WI), 1 I..Ig total RNA, 51..11 of 5x buffer, 1.251..11 of 10 mM dNTP
mix, 2.25 1..11 RNAse free water, and 1 1..11 (200 units) of Moloney Murine Leukemia Virus
Reverse Transcription (M-MLV RT, Cat #: M170, Promega, Madison, WI) and heated at

3rC for 1 hr. Water was used as a no-template control instead of total RNA. The
qPCR was performed using primer sets specific for CNTF (Mm00446373_m1 and
Rn00755092_m1), Nos1 (Mm00435175_m1 and Rn00583793_m1), HTR1A (5HT1A;
Mm00434106_s1 and Rn00561409_s1), GapOH (4352339E), and Ywhaz (Rn00755072)
(all from Applied Biosystems, Carlsbad, CA).

Histology
Mice were transcardially perfused with ice-cold PBS, pH 7.4, until the liver
became clear (approx. 10-20 ml) followed by 10 ml of ice-cold 4% paraformaldehyde in
0.1 M phosphate buffer. Brains were dissected out and immediately placed in ice-cold
4% paraformaldehyde to postfix overnight followed by cryoprotection in 30% sucrose in
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0.1 M phosphate buffer overnight. Serial coronal brain sections of 30 IJm thick were cut
on a Leica SM 2000R freezing stage sliding microtome and stored in anatomical order in
24-well plates filled with Millonig's buffer. Double immunofluorescent staining for GFAP
(MAB3402, 1: 1000, Millipore, Billerica, MA) and 5HT1 A (AB5406, 1:300, Millipore,
Billerica, MA) was performed using appropriate secondary antibodies conjugated with
Alexa488 (1 :500 goat anti-mouse) and Alexa546 (1 :500; goat anti-guinea pig; Molecular
Probes; Eugene, OR). For BrdU staining, starting at a random point along the
rostrocaudal axis of the brain sections stained included those approximately between
stereotaxic coordinates (caudal to Bregma) 1.18 to 0.14 mm for SVZ and -1.34 to -3.08
mm for hippocampal formation in the mouse (Franklin and Paxinos, 1996). Sections for
rats were approximately between 1.6 to 0.2 mm for SVZ and -2.3 to -4.52 mm for
hippocampal formation in the rat (Paxinos and Watson, 1986). Every sixth section (180
IJm apart) through the SVZ and hippocampal formation was immunostained against
BrdU (MAB3510, mouse IgG, clone BU-1, 1:100,000; Millipore, Billerica, MA). Briefly,
brain sections were incubated in 50% formamide in 2X SSC at 65°C for 2 h, rinsed in
fresh 2X SSC, incubated in 2N HCI at 3rC for 30 min, neutralized in 0.1 M boric acid,
pH 8.5, for 10 min. Next, sections were sequentially incubated in 10% normal horse
serum for 30 min, primary antibody overnight at 4°C, biotinylated horse anti-mouse IgG
(1 :800; Vector Laboratories, Burlingame, CA) for 1 hr, and avidin-biotin complex
conjugated with peroxidase for 1 hr (1 :600; Vector Laboratories). All incubations were
carried out at room temperature unless otherwise noted. In between steps, the sections
were rinsed 3 x 10min. The chromogen reaction was performed with 0.04% 3,3'diaminobenzidine (05637, Sigma-Aldrich) solution containing 0.06% nickel ammonium
sulfate and 1% hydrogen peroxide in 0.05 M Tris buffer-HCI. Sections were then rinsed
in 0.1 M phosphate buffer, mounted on gelatin coated glass slides in anatomical order,
and cover slipped in Permount (SP15, Thermo Fisher Scientific, Pittsburg, PA).
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Unbiased stereological counts and statistics
The number of BrdU+ nuclei in the SVZ of each brain was estimated using a
motorized Leica DMIRE2 microscope and an unbiased optical fractionator stereological
method (Stereologer; Stereology Resource Center, Chester, MD) (Baker et aI., 2004).
For the SVZ, the reference space was defined as an -50 IJm-wide strip of the entire
lateral of all the lateral ventricle encompassing dorsoventrally the ventral tip and the
dorsolateral triangular regions of the lateral ventricle, rostrocaudally from the genu of the
corpus callosum to the caudal end of the decussation of the anterior commissure, and
laterally the boundary between the SVZ and striatum. Within the reference space, BrdUpositive nuclei were counted in defined frames (frame size: 2000 IJm2, frame height: 15
IJm, guard height: 2 IJm, frame spacing: 100 IJm) and the total number of BrdU-positive
cells in a brain was calculated by the software as: n = number of nuclei counted x
1/section sampling fraction x 1/area sampling fraction x 1/thickness sampling fraction. A
modified unbiased stereology protocol was used to count the BrdU+ cells in the SGZ of
the dentate gyrus (West et aI., 1991). Briefly, the total number of BrdU+ cells between
the granule cell layer and hilus of the dentate gyrus that were within two cells body
distance from the granular layer of the dentate gyrus was counted bilateral from the
stereological coordinates previous stated. The total number of cells is calculated by the
modified formula for rare events: n = number of nuclei counted x 1/section sampling
fraction = total number of cells counted x (1/ (1/6)). All analysis was done bilaterally
except for in rats, in which a unilateral count was performed due to the other half of the
brain was used for mRNA analysis. All analyses were performed blindly. Statistical
analyses were performed with the Student's unpaired t-test using Excel software
(Microsoft, Redmond, WA). A value of p < 0.05 was considered statistically significant.
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RESULTS

5HT1A receptors co-localization in SVZ astrocytes in C57BU6J mice
Astrocytes in different areas of the brain are heterogeneous populations that can
express different amounts and types of receptors (Emsley and Macklis, 2006).
Interestingly, 5HT1A is found in highest abundance in astrocytes of rats in the two
regions of the brain where neurogenesis occurs throughout life (Whitaker-Azmitia et aI.,
1993). In mice, 5HT1A staining also co-localized with GFAP in the SVZ (Figure 1A-C).
This was confirmed in confocal microscopy z-stack images showing that most of 5HT1A
staining is co-localized with GFAP in addition to a few putative axon terminals,
presumably presynaptic receptors of serotonergic projections (arrows in Figure 10-F).
However, colocalization with synaptophysin remains to be done. In the dentate gyrus,
5HT1A immunostaining is co-labeled with GFAP, including the SGZ (Figure 1G-I).

5HT1A agonist 8-0H-DPAT does not increase neurogenesis in adult C57BU6J
mice
We intended to test the role of 5HT1 A directly in CNTF-/- mice and their
littermates but wanted to first test 8-0H-OPAT in less expensive C57BLl6J mice. The
latter are the most commonly used strain in neuropharmacological research and our
normal strain that we currently and previously have used to show changes in SVZ
proliferation after 3 day drug treatments (Emsley and Hagg, 2003, Yang et aI., 2008).
Male C57BLl6J adult mice received 1 mg/kg/daily over 3 days using subcutaneous Alzet
osmotic mini-pump containing saline or saline plus the active enantiomer of 8-0H-OPAT.
This dose was used by others who have shown 8-0H-OPAT to promote neurogenesis in
both rats and mice (Santarelli et aI., 2003, Soumier et aI., 2010). BrdU was injected
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twice daily at 50 mg/kg Lp. per injection. After an unbiased stereological analysis, we
found no differences in either BrdU+ cells in the SVZ (Figure 2A) or SGZ (Figure 2B).
Separately, we used higher doses and found that 3 or 10 mg/kg per day bolus injections
in the wild type background of our CNTF mice (essentially C57BLl6) also did not induce
neurogenesis (data not shown; n=4 per group). The osmotic pump was chosen in order
to give a constant level of drug over the 3-day drug treatment in light of the 26 min halflife of 8-0H-OPAT in the brain (Perry and Fuller, 1989). Others have shown that the
SGZ neurogenesis was increased following 28-day osmotic pump administration of 1
mg/kg/day by osmotic pump (Santarelli et aI., 2003). Therefore, C57BLl6J mice
received saline or 8-0H-OPAT for 28-days using two 14-day Alzet osmotic pumps. To
identify proliferating cells, BrdU was injected twice-daily 50mg/kg Lp. over the last 3 days
with the last injection two hours before sacrifice. The 8-0H-OPAT mice did not show an
increase in BrdU+ nuclei in the SVZ (Figure 2C) or SGZ (Figure 20). Lastly, we did not
observe the typical serotonergic behavior (forepaw treading, flat body posture, and
weaving of the head) that has been described in rats (Tricklebank et aI., 1985) in any of
these 8-0H-OPAT-treated mice.

8-0H-OPAT does not increase CNTF expression in C57BU6J mice
It was possible that 8-0H-OPAT failed to induce neurogenesis because it does
not induce CNTF. We had shown that increases in CNTF cause increased
neurogenesis (Emsley and Hagg, 2003, Yang et aI., 2008). There were not changes in
CNTF mRNA in the SVZ and hippocampal formation either acutely after 3-day infusion
(Figure 3A) or chronically after 28-day infusion (Figure 3B) in C57BLl6J mice. In the
same tissue, we measured 5HT1A mRNA to confirm there was not a down-regulation of
the receptor after the administration of 8-0H-OPAT. After 3 days infusion, 5HT1A was
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decreased by -20% in the SVZ (Figure 3C), but not the hippocampal formation (Figure
3D). Lastly, to find additional evidence for the expected effects of 8-0H-DPAT, we
measured neuronal Nitric Oxide Synthase (nNOS) mRNA levels in the same tissue, as
these were shown by others to decrease in the hippocampus of B6129SF2 mice 1 day
after treatment and to diminish completely by 7 days (Zhang et aI., 2010). In our
C57BLl6J mice, nNOS mRNA did not decrease after acute (Figure 3E) or chronic
(Figure 3F) administration of 8-0H-DPAT.

8-0H-OPAT does not stimulate neurogenesis or CNTF in adult 129SvEv mice
It is possible that our negative results after 8-0H-DPAT treatment were related to
the C57BLl6J strain. We, therefore, repeated the 8-0H-DPAT experiment of the study
by Santarelli et al. (2003), in which they used male 129SvEv mice to show that 8-0HDPAT increased neurogenesis specifically through 5HT1A. Here, male 129SvEv mice
from the same vender were first treated with a 3-day Lp. injection of saline of 1 mg/kg 8OH-DPAT. There was no significant change in the BrdU+ nuclei for the SVZ (Figure 4A)
or SGZ (Figure 4B). Given the fact that the Santarelli et al. (2003) infused for 28 days
using Alzet pumps, we next also infused saline or the same dose, 1 mg/kg/day, of 8-0HDPAT. There was no significant change seen in BrdU+ nuclei in either the SVZ (Figure
4C) or SGZ (Figure 4 D). Since we did not see changes in neurogenesis, we measured
CNTF mRNA levels and found no effects in either the SVZ or the hippocampal formation
of acute (Figure SA) or chronic (Figure 5B) 8-0H-DPAT treatment groups. 5HT1A
mRNA levels were not affected after acute (Figure 5C) or the chronic (Figure 5 D)
treatments in the SVZ or SGZ. As in the C57BLl6J mice, the nNOS mRNA levels for
both acute (Figure 5E) and chronic (Figure SF) groups were not significantly affected by
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the 8-0H-DPAT treatment. As in the C57BLlSJ mice, we did not observe the typical
serotonergic behavior in any of the 8-0H-DPAT-treated 129SvEv mice.

8-0H-DPAT increases neurogenesis in adult rats, but only in the SGZ and not
through CNTF
Despite bioactivity in mice as shown by the decrease in 5HT1A after acute
treatment with 8-0H-DPAT in C57BLlSJ mice, we wanted to further verify that 8-0HDPAT was active. The literature on the use of 8-0H-DPAT in rats is much more
extensive, including behavioral effects (Tricklebank et aI., 1985) and its ability to
increase hippocampal neurogenesis (Banasr et aI., 2004, Huang and Herbert, 2005,
Soumier et aI., 2010). Thus, male Sprague-Dawley rats were injected daily i.p. with
saline or 1 mg/kg 8-0H-DPAT over 3 days. Within minutes of 8-0H-DPAT injection the
rats exhibited typical serotonergic behavior, verifying that our drug was effective at
eliciting a serotonergic response. The number of BrdU+ nuclei in the SGZ was
increased by 43% after the 3-day treatment (Figure SB, D, and F). In contrast, the SVZ
showed no change in the number of BrdU+ nuclei (Figure SA, C, and E). Since we
found that 8-0H-DPAT increased neurogenesis in the rat SGZ, we assessed whether
this was mediated by an increase in CNTF. However, there were no changes in CNTF
mRNA levels in the SVZ or hippocampal formation (Figure 7A). To test whether the
difference between the SGZ and SVZ neurogenesis was related to the presence of
functional 5HT1A, we measured the effects of 8-0H-DPAT on nNOS mRNA levels. The
nNOS mRNA levels were decreased by 50% in the hippocampal formation, but were not
affected in the SVZ (Figure 7B). Lastly, 5HT1A mRNA levels were checked to see if
there was a down regulation of the receptor. 5HT1A was not significantly changed in the
SVZ or SGZ (Figure 7C).
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DISCUSSION
Like others, we find that 8-0H-DPAT increases neurogenesis in the adult rat
SGZ (Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). We wanted
to define the role of CNTF in this neurogenic response, given the commonality between
5HT1A and D2 receptors, i.e., both lowering cAMP and found on astrocytes. CNTF
seems not involved in the neurogenic response to 8-0H-DPAT, as it did not increase in
the hippocampal formation. The lack of changes in CNTF expression in rats and mice,
and in the SVZ and hippocampal formation suggests that, unlike the D2 receptor (Yang
et aI., 2008), 5HT1A does not inhibit cAMP in astrocytes in vivo. In fact, a recent study
showed that the R-isoform of 8-0H-DPAT did not decrease forskolin-stimulated
increases in cAMP in the membranes isolated from rat dorsal raphe nucleus (Valdizan et
aI., 2010). If not CNTF, what then might regulate the neurogenic response to 5HT1A
agonist in the rat SGZ? The difference between the neurogenic response in the SVZ
and SGZ and its correlation with the decrease in nNOS mRNA levels suggests that
5HT1A activation in the SGZ decreases nNOS signaling, which results in an increase in
neurogenesis. In fact, NO appears to reduce proliferation and nNOS inhibition in the
CNS of adult mammals causes an increase in neurogenesis in the SVZ (Matarredona et
aI., 2005) and hippocampal formation (Nakagawa et aI., 2002a, Nakagawa et aI., 2002b,
Gass and Riva, 2007, Gur et aI., 2007). In cultured hippocampal neurons, 8-0H-DPAT
was shown to decrease nNOS, which decreases NO production, increasing
phosphorylation of cAMP response element binding protein (CREB) which presumably
increases transcription (Zhang et aI., 2010). Furthermore, in CREBal. mutant mice there
was a 52% increase in BrdU+ nuclei in the SGZ compared to wild-type mice (Gur et aI.,
2007). Moreover, a decrease in neurogenesis was observed when CREB activity was
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down regulated by expressing a dominant-negative CREB (Nakagawa et aL, 2002a,
Nakagawa et aL, 2002b). Pharmacological inhibition of NO by L-NAME was shown to
increase neurogenesis in the SVZ of adult mice (Romero-Grimaldi et aL, 2008). This
suggests that since there were no changes observed in the mRNA levels of nNOS after
8-0H-DPAT treatment in the SVZ of rats and the SVZ and SGZ of mice that 5HT1A
does not modulate their nNOS levels. Besides its classical inhibition of adenylyl cyclase
(Cornfield et aL, 1991), 5HT1A also can couple to other signaling pathways such as
phospholipase C (Fargin et aL, 1989), mitogen-activated protein kinases (Della Rocca et
aL, 1999) and AKT (Cowen et aL, 2005), which playa role in adult neurogenesis (Ma et
aL, 2009, Kinsler et aL, 2010, Manning et aL, 2010). These pathways could signal
independent of adenylyl cyclase or converge on different adenylyl cyclase subtypes to
increase or decrease cAMP (Raymond et aL, 1999). Although the exact intracellular
mechanism of action of 8-0H-DPAT on neurogenesis in the rat SGZ remains to be
determined, the finding that it does not act through CNTF should enable the
development of drug combinations. For example, one could expect an additive effect on
the levels of SGZ neurogenesis by combining 5HT1A agonist and D2 agonists, the latter
stimulating neurogenesis by increasing CNTF (Yanget aL, 2008).
In rats, 8-0H-DPAT was shown to increase BrdU+ nuclei in the SVZ 4 hours after
i.p. injection although the data for longer times were not reported (Banasr et aL, 2004).
Our 3-day treatments did not result in any changes in SVZ BrdU+ nuclei. Other than
strain differences, we do not know the reason for this apparent discrepancy. Thus, the
reason for the lack of a neurogenic effect of 8-0H-DPAT in the rat SVZ remains to be
determined, but the presence of 5HT1A in the SVZ suggests that they are not functional
in the SVZ astrocytes under normal conditions. Others have shown that astrocytes from
2-day old Sprague-Dawley rat pups cultured from various other brain regions express
non-functional 5HT1A in culture (Hirst et aL, 1998). If so, this would suggest that
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astrocytes in different eNS regions can function entirely different, as also suggested by
their different phenotypes (Emsley and Macklis, 2006). Another possibility is that 5HT1A
in the two different regions of the brain have differences in intracellular coupling and/or
signaling as it has been shown with different cell types in vitro (Raymond et aI., 1999).
The activity of 5HT1A was shown to be impacted by alterations in any of the guanine
nucleotide-binding protein G(i), alpha subunit (G ia ), in particular, alterations in the levels
of Gia1 was shown to have a greater impact on 5HT1A activity (Liu et aI., 1999, Lin et aI.,
2002, Valdizan et aI., 2010). It remains to be determined whether there are different
levels of the G;/G o protein isoforms accessible to the 5HT1A for coupling in the SVZ
versus the SGZ, but it would explain why there is an apparent difference in functional
activity. Another possibility is that 8-0H-DPAT acts on other, differently expressed,
receptors in the two structures. The R-enantiomer of 8-0H-DPAT is considered to be
the prototypical selective agonist for 5HT1A as shown by radio ligand binding
(Middlemiss and Fozard, 1983). However, the use of transgenic mice and
pharmaceutical inhibitors have shown that 8-0H-DPAT has agonistic activity on 5HT7
(Hedlund et aI., 2004) and o2-adrenoceptors (Heusler et aI., 2010). Finally, the
difference in the neurogenic response between the SVZ and SGZ most likely represents
the different physiological roles of the two systems, and differences in the serotonergic
neurons that innervate these regions. In turn, it means that hippocampal neurogenesis
can be stimulated by 5HT1A agonists without affecting the olfactory neurogenesis,
perhaps opening up opportunities for region-selective drug treatments to increase new
neuron formation.
Our results also point to remarkable differences between rats and mice with
regards to the 5HT1A function and its role in neurogenesis. The lack of any effects of 8OH-DPAT in our mice, other than a 20% down-regulation of 5HT1A, suggests that the
receptors are not fully functional in these strains of mice. Previously, 8-0H-DPAT
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administration was shown to induce hypothermia in mice and rats to a different extent,
suggesting the 5HT1A heterogeneity is present between mice and rats (Moser, 1991).
In their landmark paper, Santarelli et aL (2003) report that the same dose and duration of
8-0H-OPAT causes an increase in BrdU+ nuclei in the SGZ of 129SvEv mice but not in
5HT1A-/- mice. The neurogenic effect of 8-0H-OPAT was replicated in 129SvEv mice
within the same laboratory (B. Samuels, personal communication). A few differences
might explain the apparent discrepancy between our studies. First, we used the active
enantiomer whereas they used the racemic mixture of 8-0H-OPAT. It is unlikely that the
S-enantiomer, a partial agonist, would have stimulated neurogenesis through other
receptors or mechanisms, as it was ineffective in 5HT1A-/- mice (Santarelli et aI., 2003).
Another potential difference is the stress caused by their behavioral testing resulted in a
depressed baseline of neurogenesis in controls. Stress can have both deleterious and
stimulatory properties depending on the type (Sa hay and Hen, 2007, Schoenfeld and
Gould, 2011). The 129SvEv mice might be unique as the neurogenic effect of fluoxetine
(Santarelli et aL, 2003) is not seen in BALB/cJ mice within the same laboratory (Holick et
aL, 2008) or BALB/cJ and C57BLl6J mice in another laboratory (Navailles et aL, 2008).
Our results are consistent with the finding that a 7 day treatment of 8-0H-OPAT did not
increase neurogenesis whereas a single injection increased proliferation by 55% at 24 hr
in the SGZ of C57BLl6 mice (Klempin et aL, 2010). Our 3-day data suggest that more
than a single injection might be ineffective as a neurogenic treatment. Whatever the
differences, we propose that 5HT1A does not playa role in normal neurogenesis in adult
mice, although it has a clear role in rats. In fact, 5HT1A-/- mice show no differences in
the number of BrdU+ nuclei under baseline conditions (Santarelli et aL, 2003).
In light of the differences between rats and mice, what are the potential
implications for the role of 5HT1A in neurogenesis in humans? This has important
implications for the depression field because of the unresolved debate about whether or
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not changes in neurogenesis playa role in depression (Kempermann, 2008, Thomas
and Peterson, 2008). 5HT1A protein has an 89% homology between rats and humans,
94% between rats and mice, and 86% between mice and humans (Clustal W Software,
European Bioinformatics Institute, Cambridge, UK). However, there could be differences
in the ligand binding regions or availability of coupling intracellular proteins. Also, rats
and humans have a different neuroanatomical distribution in 3H-8-0H-DPAT binding
(Duncan et aI., 1998). Rats have high binding in the dentate gyrus molecular layer
whereas humans have relatively low binding. Humans and rats have high binding in CA1 stratum radiatum, but only humans have high binding in the CA-1 pyramidal cell layer.
These differences could playa role in augmenting or diminishing the neurogenic effects
seen in rats and make translation to humans more uncertain. We propose that based on
the major species differences much more research is needed to define the potential role
of 5HT1A in human hippocampal neurogenesis and the consequences of such a
speculative mechanism for clinical depression.
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Figure 1. 5HT1A is present in astrocytes in the SVZ and SGZ of adult C571B6J mice.
5HT1A (A) and GFAP (B) are co-localized (C) in the SVz.

Confocal microscopy shows that 5HT1A (0) and GFAP (E) are almost exclusively colocalized (F), as indicated in the z-stack, except for a few putative axon terminals,
presumably presynaptic receptors of serotonergic projections (arrows). In the dentate
gyrus, 5HT1A (G) and GFAP (H) also shows co-localization (I), including in the SGZ.
Scale bar 100 IJm (A-C , H-I), 10 IJM (O-F). CC = corpus callosum , GCl = granule cell
layer, H = hilus, lV = lateral ventricle , STR = striatum .
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Figure 2. 5HT1A agonist 8-OH-OPAT does not increase proliferation in C57816J mice.
R-8-0H-DPAT was administered s.c. with a dose of 1 mg/kg delivered via Alzet osmotic
pump for either 3 days or by two 14-day Alzet pumps for a total of 28 days to C57B/6J
male mice. There were no significant changes in BrdU+ nuclei acutely after 3 days, in
the SVZ (A) or SGZ (B) or chronically after 28 days in the SVZ (C) or SGZ (D). BrdU
was given i.p. twice daily for 3 consecutive days with the last injection 2 hours before
euthanasia and processing for histology. n= 5, 6 in each group for 3 day and 28 day,
respectively.
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Figure 3. 8-0H-OPAT does not alter CNTF or nNOS mRNA, but reduces 5HT1A mRNA
levels in C57BI6J mice.
CNTF mRNA levels were not changed acutely (A), after 3 days, or chronically (8), after
28 days of 5HT1A agonist treatment in the SVZ and hippocampal formation. 8-0HOPAT did cause a significant decrease in 5HT1A mRNA levels (C) (p=O .0499) in the
SVZ but not the hippocampal formation after 3 days of 1 mg/kg of 8-0H-OPAT. 5HT1A
mRNA levels did not change in the SVZ or HF after 28 days of 8-0H-OPAT infusion (0).
nNOS mRNA levels in the SVZ and hippocampal formation did not significantly change
acutely (E) or chronically (F). * signifies p<O.05 , n= 4, 5, 6 in each group for saline 3
day, 8-0H-OPAT 3 day, and 28 day, respectively.
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Figure 4. 8-0HDPA T does not increase proliferation in the SVZ or SGZ in 129SvEv
mice.
R-8-0H-DPAT was administered with a dose of 1 mg/kg delivered either by daily i.p.
injection for 3 days or s.c. via Alzet osmotic pump for 28 day to 129SvEv male mice.
There were no changes in the number of BrdU+ nuclei in the SVZ (A) or SGZ (B) acutely
or the SVZ (C) or SGZ (D) chronically. n= 5 in each group.
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Figure 5. 8-0H-OPAT does not alter mRNA levels of CNTF, 5HT1A or nNOS in
129SvEv mice.
CNTF mRNA levels were not changed acutely (A), after 3 days, or chronically (8), after
28 days of treatment in the SVZ and hippocampal formation . 8-0H-OPAT did not cause
a significant decrease in 5HT1 A mRNA levels in the SVZ or hippocampal formation after
3 days (C) or 28 days (0) of 1 mg/kg of R-8-0H-OPAT. nNOS mRNA levels in the SVZ
and hippocampal formation did not significantly change acutely (E) or chronically (F). n=
5 in each group.
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R-8-0H-DPAT was
administered with a
dose of 1 mg/kg
delivered by daily
i.p. injection for 3
days in SpragueDawley rats . BrdU
labeling in the SVZ
(A) and SGZ (B) of
sal ine treated rats .
BrdU labeling in the
SVZ (C) and SGZ
(D) of 8-0H-DPAT
treated rats. There
was no significant
difference in the
number of BrdU+
nuclei in the SVZ of
rats (E). There was
a significant 43%
increase in the
number of BrdU+
nuclei in the SGZ in
rats (F). * signifies
p<0 .05 , n= 5 in
each group. Scale
bar 500 ~m (A and
C) and 100 ~m (B
and D).
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CHAPTER THREE
ADAM21-DEFICIENT MICE HAVE NO APPARENT PHENOTYPE
BEFORE OR AFTER SPINAL CORD INJURY
INTRODUCTION
The ADAMs are multi-domain transmembrane proteins, constituting a subfamily
of the metzincin superfamily, and mostly known for their proteolytic sheddase activity
and their integrin-binding properties (Wolfsberg et aL, 1995, Yang et aL, 2006). MMPs
are similar in the N-terminus to ADAMs as they contain a prodomain and
metalloproteinase domain, but ADAMs also are comprised of several additional
domains: disintegrin, cysteine rich, EGF-like repeat, and cytoplasmic tail (Edwards et aL,
2008). The ADAMs have been linked to several disease processes such as asthma
(King et aL, 2004, Haitchi et aL, 2005), inflammation (Charrier-Hisamuddin et aL, 2008,
Koller et aL, 2009, Pruessmeyer and Ludwig, 2009), wound healing (Charrier et aL,
2005, Hodgkinson et aI., 2010), cancer (Lu et aI., 2008), and neurological diseases
(Gerst et aL, 2000, Barrette et aI., 2010). The metalloproteinase is of interest because of
the potential for drug intervention with a small molecule that could inhibit its catalytic
activity.
MMPs have been widely studied in the brain (Agrawal et aL, 2008) and found to
be differentially regulated after spinal cord injury (Zhang et aI., 2011 a). Deletion of the
metalloproteinase genes MMP9 (Noble et aL, 2002) and MMP12 (Wells et aL, 2003)
resulted in improved functional recovery and reduced/attenuated barrier disruption
following spinal cord injury. Conversely, deletion of MMP2 resulted in impairment of
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locomotor recovery, reduced white matter sparing, and widespread reactive astrogliosis
following spinal cord injury (Hsu et aI., 2006).
However, the literature on ADAMs after spinal cord injury, with the exception of
expression data, is limited to our finding that ADAM8 is association with angiogenesis
after spinal cord injury (Mahoney et aI., 2009). ADAM8-/- mice do not have an overt
phenotype following spinal cord injury (Arnold and Hagg, unpublished data). ADAM21 is
of interest because of the robust immunostaining in highly plastic areas: new adult
primary olfactory neurons and their axons growing into the CNS, radial glial cells during
postnatal development, and tanycyte-like cells in the in the adult subventricular zone
where neurogenesis occurs (Yang et aI., 2005). ADAM21 has a catalytically active
metalloproteinase (Hooft van Huijsduijnen, 1998). This evidence leads to the possibility
that like its MMP relatives, ADAM21 could be involved in the processes which occur
after spinal cord injury and contribute to secondary degeneration, repair, or plasticity.
In the EAE model of demyelination, TIMP-1 deficient mice exhibited a delay in
myelin formation which correlated with the decreased number of astrocytes found in the
white matter (Crocker et aI., 2006, Moore et aI., 2011). Thus inhibition of
metalloproteinases might result in increased spared white matter which would result in
locomotor recovery following spinal cord injury. Additionally, CGRP can be induced by
cytokines such as TNFa (Schafers et aI., 2003) resulting in hypersensitivity to nonnoxious stimuli (allodynia). Since several ADAMs have been linked to activation of
TNFa, it is plausible that activation of TNFa or other pro-inflammatory cytokines could be
a mechanism in which ADAM21 could have a role in pain development after spinal cord
injury (Karkkainen et aI., 2000, Doedens et aI., 2003, Hooper et aI., 2005, Hikita et aI.,
2009, Pruessmeyer and Ludwig, 2009). Notch is another known target of ADAMs, in
particular ADAM10 and possibly ADAM17, which requires shedding of its ectodomain
before a second cleavage is required for release of Notch intracellular domain by y-
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secretase (Wen et aI., 1997, Qi et aI., 1999, Brou et aI., 2000, Mumm et aI., 2000, Deuss
et aI., 2008). Modulations by metalloproteinases in Notch signaling following spinal cord
injury could affect cell proliferation, angiogenesis, or transcription of proteins (Yamamoto
et aI., 2001, Fassbender et aI., 2011 a). Lastly, ADAM21 's presence in radial glial cells,
which could potentially act as neural stem cells in the adult spinal cord resulting in
neuronal repair and regeneration after spinal cord injury.
Here we investigated the functional outcomes after a T9 spinal cord injury in
adult ADAM21-deficient mice by assessing locomotion, balance, and fine motor skills, as
well as thermal nociception over a 6-week period. Additionally, we measured
histological outcomes such as spared white matter, and the area occupied by CGRP and
GFAP immunostaining at and around the injury epicenter.

METHODS

Animals
A total of 55 mice were used, i.e., adult male and female littermates from each
genotype were age and gender matched. They were bred in house from heterozygous
B6.129P2-ADAM21tm1Dgen/J mice (stock# 006431, Jackson Laboratory, Bar Harbor,
ME, USA; crossbred a minimum of 3 times with C57B/6 mice) and crossbred in house 2
more times with C57B/6J mice (stock# 000664, Jackson). The deleted gene was
replaced by a Lac-z containing cassette. The genotyping protocol was supplied by
Jackson laboratory (refer to
http://jaxmice.jax.org/protocolsdb/f?p=116:2:442721623684068::NO:2:P2_MASTER_PR
OTOCOL_ID,P2_JRS_CODE:1256,006431). All animal procedures were performed
according to University of Louisville Institutional Animal Care and Use Committee
protocols and the National Institutes of Health guidelines.
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Spinal cord injury
Mice were anesthetized by an intraperitoneal injection of 0.4 mg/g body weight
Avertin (2,2,2-tribromoethanol in 0.02 ml of 1.25% 2-methyl-2-butanol in saline, SigmaAldrich, St Louis, MO). A 50 kdyn T9 contusion injury was made using an Infinite
Horizons (IH; Precision Systems and Instrumentation, LLC, Lexington, KY) impactor
after a laminectomy was made at T9 spine level. Sham animals received the same
treatment as injured animals short of the impact on the spinal cord. All animals received
subcutaneous injection of 2 ml saline (1 ml before and after injury) and 0.1 ml of
gentamicin (20 IJg/ml stock, ButlerSchein, Dublin, OH). Gentamicin was also given on
day 2 and 4 post injury. Bacitracin ointment (Qualitest Pharmaceuticals, Huntsville, AI)
was applied to the sutured wound area. Once animals were fully awake, twice-daily
analgesia was administered subcutaneously for the first 48 hours of 0.1 ml of a 15 IJg/ml
stock solution of buprenorphin (Reckitt Benckise, Hull, England). Animals were placed 5
per cage on Alfa Dry bedding and recovered on a water circulating heating pad
overnight. Animal bladders were manually voided, as needed, once or twice daily until
automatic voiding returned spontaneously, usually within 7-10 days. Metal sutures were
removed between 7 and 10 days post injury. As in indicator of overall health and growth
of the animals, the weight was checked prior to and after injury. Animals from each
group continually gained weight and no significantly different weight gain was observed
between genotypes.

BMS analyses
Mice were tested for hindlimb locomotor function before injury to establish a
baseline, and weekly after injury beginning at 7 days using the Basso Mouse Scale
(BMS) (Basso et aI., 2006). Animals were place in a 47-inch metal pool and observed
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for 4 minutes by two trained individuals who were blinded to genotype and injury. Only
individuals certified by Dr. Michelle Basso at Ohio State University were used in the
behavior testing. Animals were given a score ranging from 0 to 9, with a score of zero
having no movement of the hindlimbs and 9 signifying a normal animal with proper
hindlimb coordination, trunk stability, paw placement, and tail position. Animals with a
score of greater than or equal to 5 received a subscore ranging from 0 to 11.

Beam Walk analyses
The balance and fine motor skills were tested at baseline and weekly after injury
using a graded series of suspended on 47 cm long metal beams of various widths: 4mm,
8mm, 12mm, 16mm, and 20mm, which was modified from the previously described
beam walk method (Hill et aI., 2009). In short, the narrowest beam a mouse could walk
across was used for testing. The animals were scored based on beam size and the
number of errors while crossing the beam. The final score was obtained by averaging
the scores of two trials obtained on smallest crossable beam for each animal. Details of
the scoring sheet are described elsewhere (Hill et aI., 2009).

Hargreaves analyses
Thermal nociception thresholds in mouse forepaws and hindpaws were
evaluated using a Hargreaves device (IITC 390 Plantar Test; IITC Life Sciences, CA).
The intensity of the heat source was set at 30%. The mice were placed in a Plexiglas
testing chambers with a glass floor that was maintained at 3rC. The mice were allowed
to acclimate to the apparatus for twenty minutes. The radiant heat source was placed
alternately under the plantar surface of each forepaw and hindpaw until the animal
withdrew its paw from the stimulus. The latency time was recorded for each forepaw
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and hindpaw. There was a cutoff time of twenty seconds in order to avoid tissue
damage. At each time point, testing was repeated five times per animal with a minimum
of 5 minutes between each trial. The latency of withdrawal for each paw was averaged.
Mice were tested before injury to establish at baseline and after injury weekly beginning
at 7 days.

Tail Flick
Thermal nociception thresholds in the mouse tail was evaluated using Tail Flick
Analgesia Meter (Columbus Instruments, Columbus, OH) with the intensity set at 6
resulting in a baseline of around a 2 second withdrawal time. Mice were restrained in
the Tailveiner (TV-150, Braintree Scientific, Braintree, MA) and the tail was placed in the
groove with a shuddered light. Once the shutter was turned off, the tail-flick response
was measured using automatic detection. The trial was repeated 3 times for each
animal with no less than 5 minutes between trials. Mice were tested at baseline and
weekly after injury.

Histology
Mice were anesthetized and transcardially perfused with 20 ml of ice-cold PBS,
pH 7.4, and 10 ml of ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer.
Afterwards, a 1 cm segment of the spinal cords was carefully dissected out, post-fixed in
4% paraformaldehyde overnight, and subsequently stored in Millonigs solution. Before
freezing, the spinal cord segments were cryoprotected in 30% sucrose in 0.1 M
phosphate buffer overnight followed by embedding in Tissue Freezing Medium (TFM-C,
Triangle Biomedical Sciences, Durham, NC). Twenty consecutive transverse 20 J.Jm
sections per 1 mm were cut on a cryostat, mounted on charged microscope slides, and
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stored at -20°C until staining. Additionally, the spinal cords of a group of na"ive animals
from each genotype was also cut in 20 IJm sections from T7 to T11 and every section
was collected. One in every 10 sections from the na·ive spinal cords was used for
staining.
A modified eriochrome cyanine staining protocol was used to detect white matter
tracts. Briefly, one in every 5 sections was thawed for 1 hour at 3rC, immersed in
xylene (2 x 30 minutes), followed by a graded alcohol series ( 3 min 100% EtOH, 3 min
70% EtOH, 3 min 50% EtOH, 2 min dH 2 0), 10 minutes in eriochrome cyanine reaction
RC stain (0.16% eriochrome cyanine RC in 0.4 FeCI 3 and 0.4% H2S04 ), rinsed twice in
tap water, differentiated for 30 seconds in 0.5% NH 4 0H, rinsed twice in tap water to stop
differentiation, and allowed to dry overnight at room temperature. Slides were then
placed in xylene for 10 minutes and cover slipped using Permount (SP15, Thermo
Fisher Scientific, Pittsburg, PAl. The area of most myelin loss was used to determine
the epicenter by calculating total number of pixel stained using manual threshold in
ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, http://imagej.nih.gov/ij/, 1997-2011.)
Adjacent sections were stained for GFAP, CGRP, j3-galactosidase (from the Lacz reporter gene), and ADAM21. Sections were thawed for one hour and the dried Tissue
Freezing Medium was carefully removed with forceps. In short, the sections on the
slides were circled with a hydrophobic barrier using a Super PAP Pen (Cat.# 008899,
Invitrogen, Carlsbad, CAl, rinsed twice with 0.1 M Tris-Buffered Saline containing 0.3%
Triton-X (TBS-Tr), incubated 1 hr in 5% donkey serum in TBS-Tr at room temperature,
incubated overnight in 4°C primary antibody containing 5% donkey serum in TBS-Tr and
mouse anti-GFAP (1 :1000, Cat.# MAB3402, clone GAS, Millipore, Billerica, MA), rabbit
anti GFAP (Cat.# Z0334, Dako, Carpinteria, CAl, rabbit anti-CGRP (1 :1000, Cat.#,
Millipore, Billerica, MA), mouse anti-j3-galactosidase (Cat.# 23781, Promega, Madison,
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WI), or rabbit anti-AOAM21 (1 :1000, Cat.# AB19001, Millipore, Billerica, MA). Next, the
slides were rinsed 3 times in 0.1 M Tris-Buffered Saline (TBS), incubated for one hour
containing 5% donkey serum in TBS at room temperature with donkey anti-mouse or
donkey anti-rabbit secondary Alexa Fluor antibody (1 :200, Cat.# A-21202, A-21203, and
A-21206, Invitrogen, Carlsbad, CA), rinsed 3 times in TBS, and cover slipped using
Fluormount (Cat.# 0100-01, Southern Biotech, Birmingham, Alabama). Images for
analysis were taken with a 10x objective for eriochrome cyanine staining and GFAP
immunostaining and a 20x objective for CGRP immunostaining on a OM 6000 Leica
upright microscope using the automated stitching Surveyor software (Objective Imaging,
Cambridge, UK) in conjunction with an Oasis Automation Controller (Objective Imaging,
Cambridge, UK) which drives the motorized stage. CGRP images from the second
series of naive mice were taken using a z-stack of 15 !-1m with a 5 !-1m step.

Histology image analysis
The total number of pixels of spared white matter visualized byeriochrome
cyanine staining and GFAP immunostaining was calculated using manual threshold in
ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011.) Fast Fourier Transform (FFT)
using Image Pro Plus software (version 6.2, Media Cybernetics, Inc, Bethesda, MO) was
used on injured spinal cords that were immunostained with CGRP. In short, pictures
were converted to monochrome, followed by FFT with a spectrum gain of 70 and an
area of interest (AOI) of an ellipse radius of 5,5 which corresponds to 1638 pixels per
period. Frequencies within the radius were cut. Then an inverse FFT was applied to the
original image reducing the signal to noise ratio. Then the total number of pixels was
calculated using the manual threshold in ImageJ. The AOI, dorsal horn of the spinal
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cord was boxed with two boxes (2500px x 2500px) originating at the central canal and
extending across each dorsal horn was drawn. The na·ive spinal cords were analyzed
using the same method as the spinal cord injured with the exception of the Fourier
transformation. The two sets of tissue analyzed for CGRP immunostaining, spinal cord
injured and na·ive, were not stained at the same time or analyzed by the same person.
The three-fold difference in total stained area is most likely due to higher signal of CGRP
labeling. All sections within a group were analyzed by the same person to decrease
variability.

Statistical analysis
A repeated measure ANOVA over time with covariate analysis on gender, age,
and weight with a paired Student's post-hoc t-test was used to determine significance in
all behavior data. For histological data, an unpaired Student's t-test was performed
between genotypes. A value of p :s; 0.05 was considered statistically significant. All
values are reported with standard error of the mean.

RESULTS
ADAM21 localization
ADAM21 immunostaining in uninjured wildtype adult mice was found in laminae I
and II of the dorsal horns of the spinal cord (Figure BA and 8), the region of nociceptive
innervation, and in the ependymal cells around the central canal (Inset of Figure B8).
Similar to the wildtype mice, ADAM21 immunostaining is present in ADAM21-deficient
mice in the dorsal horns (Figure BD and E) and in the ependymal cells surrounding the
central canal (Inset of Figure BE). The ADAM21-deficient mice contain a LacZ reporter
gene within the insertion cassette enabling localization of ADAM21 expression by
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immunostaining for its ~-Galactosidase (~-Gal) protein product. As expected, no
immunostaining was present in the spinal cords of wildtype mice (Figure SC). In the
sham or na"lve ADAM21-deficient mice,

~-Gal

immunostaining was present in tube-like

structures that appeared to be associated with blood vessels (Figure SF, G and H;
indicated by arrow in G and H). In the injured spinal cord, the

~-Gal

immunostaining was

occasionally seen in cells with a single leading process similar to a migrating cell were
seen in the white matter (Figure SI). In addition,

~-Gal

immunostaining appeared in cells

with morphology similar to microglia at the epicenter, rostral, and caudal to injury site
(Figure SJ).
Surprisingly, the

~-Gal

immunostaining in the ADAM21-deficient spinal cords did

not show the same pattern as seen with the ADAM21 antibody in na"lve or injured spinal
cords (Figure SA, B, D, and E). Coupled with ADAM21 immunostaining in the ADAM21deficient mice and lack of co-labeling with the

~-Gal

reporter gene, leads us to believe

the ADAM21 immunostaining in which our original hypothesis was based from does not
detect ADAM21 protein.

Behavioral comparison between ADAM21-deficient and wildtype mice.

As expected, 1 week after spinal cord injury there was a significant decrease in
the BMS scores in both ADAM21-deficient and wildtype animals that remained
significantly different from baseline 6 weeks after injury (Table 1). However, there was
not a significant difference between these two groups at any time over the 6 weeks
following the spinal cord injury. Of note, BMS scores are higher than normally seen due
to mild injury indicated by the low displacement values of the animals in this study.
Likewise, Beam walk had a significant decrease in scores 1 week following spinal cord
injury in both genotypes and remained significantly different over the 6 weeks following
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the injury (Table 1). ADAM21-deficient mice did not gain additional gross or fine
locomotor function beyond the spontaneous recovery consistently seen in mice.
At 1 week post injury, there was a significant drop in withdrawal time following
thermal stimuli; however, no significant differences was found between ADAM21deficient and wildtype mice prior or after spinal cord injury in the Hargreaves test on the
hind paws (Table 1). Tail Flick did not show any differences between genotypes or within
a genotype from baseline at any time over the 6 weeks following injury (Table 1). The
decrease in hindpaw withdrawal time indicts hypersensitivity following spinal cord injury
in both ADAM21-deficient and wildtype mice.

Epicenter histology: comparison between ADAM21-deficient and wildtype mice.
The area of white matter sparing was assessed by eriochrome cyanine staining.
There was no significant difference between the spared white matter in ADAM21deficient compared to wildtype animals at the injury epicenter, 1 mm rostral, 1 mm
caudal or the total penumbra (1 mm rostral and caudal combined) to the injury (Table 2).
In both genotypes the amount of spared white matter was approximately 50% of sham
which is consistent with the relatively high BMS scores, indicating a mild injury.
CGRP immunostaining was evaluated in order to investigate the possibility of
ADAM21 induced sprouting in the dorsal horns. At the epicenter, CGRP was decreased
significantly from the penumbra probably due to the loss of neurons at the compression
site shortly after injury. The total area of CGRP immunostaining was not found to be
significantly different after injury between ADAM21-deficient and wildtype mice at
epicenter, 1 mm rostral, 1 mm caudal, or total penumbra (Table 2). Although the degree
of CGRP staining extending past Laminae II was not quantified, there were no obvious
indications of sprouting in either genotype. The difference of the CGRP immunostaining
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in the sham animals could not be statistically analyzed due to the small sample size in
the wildtype shams (n=2). The sample size was small due to unexpected deaths in the
wildtype shams; in addition, additional wildtype shams were not available due to lack of
extra wildtype littermates of ADAM21-deficient mice. The values in the sham-operated
ADAM21 +/- mice were similar to those of the ADAM21-deficient mice (data not shown).
GFAP increased significantly at the epicenter of the injury, as expected, due to
the infiltration of glial cells and formation of the glial scar following spinal cord injury.
However, the area of GFAP immunostaining was also not found to be significantly
different between genotypes after injury or in the shams in the epicenter, 1 mm rostral, 1
mm caudal, or the total penumbra (Table 2). Since there were only two sham-operated
wildtype mice, we repeated the CGRP analysis on a new set of na'ive spinal cords using
a more precise tissue section sampling method to eliminate variations due to the
laddering effect seen in CGRP staining. In the na'ive spinal cords, there was no
difference between genotypes in total area of CGRP immunostaining from T7 to T1 0, the
area of the injury epicenter and penumbra of the other groups of mice (Table 3). This
suggests that the CGRP values seen in the two sham-operated mice were artifactually
low.

DISCUSSION
Surprisingly, J3-Gal, a reporter for ADAM21 protein in the ADAM21-deficient mice
showed expression in the null mouse that had a different cellular distribution than was
found with the ADAM21 antibody in wildtype mice. Since the ADAM21-deficient mice
contain a LacZ reporter gene, we presume that the J3-galactosidase immunostaining
shows the areas and cell types that produce ADAM21. From the J3-Gal immunostaining
ADAM21 expression appears to be localized in blood vessels in the naIve animal and

50

activated microglia, and migrating neurons in the injured animal, although this remains to
be verified by markers to co-labeling for blood vessels and microglia. However, the
antibody staining of the dorsal horn and ependymal cells seems to be non-specific for
the ADAM21 protein due to its presence in ADAM21-deficient mice and the lack of any
colocalization with the reporter,

~-Gal.

As mentioned in Chapter 4, a truncated ADAM21

transcript is still present in the ADAM21-deficient mice. Since the ADAM21 antibody
stained the last 13 amino acids of the protein, this in addition to the truncated ADAM21
transcript could explain why there is immunostaining in the ADAM21-deficient mice.
However, the only explanation for why the

~-Gal

does not colabel with ADAM21 is that

the ADAM21 antibody is not detecting the ADAM21 protein. This could explain the
absence in a phenotype involving sprouting and pain development because it seems
that ADAM21 is not localized in the dorsal horns.
Originally, due to the location in the brain of ADAM21 antibody immunostaining in
radial glial lineage cells in the SVZ and growing axons in the olfactory bulb, we believed
that ADAM21 could regulate plasticity and subsequent pain development following spinal
cord injury by regulation of cytokines such as TNFa or CX3CL which require ectodomain
shedding for activation. The initiation of the inflammatory response is thought to
originate with astrocytes following injury (Pineau et aI., 2010); astrocytes which are
damaged or at the site of damage can release cytokines such as TNFa in response to
the injury which explains the increase seen in TNFa at 1 hour following spinal cord injury
(Harrington et aI., 2005, Peng et aI., 2006, Zhang et aI., 2011b). However, since the
ADAM21 antibody is probably not an accurate depiction of cellular expression of
ADAM21, this explains why our hypothesis was wrong.
Here we evaluated the potential role of ADAM21 in the intact adult animal and
after spinal cord injury using ADAM21-deficient mice. We found no differences between
adult ADAM21-deficient mice and their littermates under normal or injury conditions in
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locomotion and coordination, fine motor and balance or thermal nociception. The similar
extent of white matter sparing between the genotypes is consistent with the similar BMS
scores, as these two are known to correlate (Basso et aI., 2006, Han et aI., 2010). Our
data from two different thermal nociception tests and the CGRP immunostaining argue
against the possibility of ADAM21 being involved in sprouting and pain development.
Since our original hypothesis suggested ADAM21 protein in radial glial cells we analyzed
normal distribution of astrocytes and their responses to injury using GFAP
immunostaining. However, there were no significant differences in the area of GFAP
seen at the injury epicenter and penumbra between the ADAM21-deficient mice and
their wildtype littermates. Thus, based on these results, ADAM21 does not seem to play
a role in spinal cord development or in responses to injury during adulthood. One caveat
to this conclusion is the fact that our injuries turned out mild, lacking clear signs of
sensory sprouting. Therefore, it is possible that ADAM21 plays a role in more severe
injuries, for example in the allodynia that develops.
Similar to ADAM21, ADAM9 was found to be widely expressed in the brain and
spinal cord, but no phenotype was found in development or in naIve adult ADAM9
knockout animals (Weskamp et aI., 2002). In addition, ADAM8, a catalytically active
metalloproteinase (Fourie et aI., 2003), has been implicated in the inflammatory
response of asthma (King et aI., 2004, Dehmel et aI., 2007), but when knocked out there
was no apparent phenotype either by defect or pathologically (Kelly et aI., 2005).
However, when ADAM8 deficient were crossed with wobbler (WR) mice, double mutant
had a more severe disease phenotype than ADAM8+/- WR mice and resulted in a
dramatic decrease in survival (Bartsch et aI., 2010). The role of ADAM9 and ADAM8
was not found to be essential for normal development or in adult mice; however, the role
of ADAM8 was elucidated only after the cross with another mutant mouse. This is
probably best highlighted in the case of ADAM9, ADAM12, ADAM15, ADAM17, and
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ADAM19. ADAM12 and ADAM15 were found not to have overlapping roles in with
ADAM9, ADAM17, and/or ADAM19 as combination of ADAM12 and/or ADAM15 did not
increase the severity when combined with combinations of ADAM9, ADAM17 and/or
ADAM19 lines (Horiuchi et aI., 2005). Through different combinations of the preceding 5
ADAMs, it was discovered that ADAM9 and ADAM19 have compensatory or redundant
roles (Horiuchi et aI., 2005). Similar to the ADAMs mentioned above, ADAM21 could
have an overlapping or redundant role with another ADAM. In a separate study, we
have not found any metalioprotease gene which solely compensates for the lack of
ADAM21 before or after spinal cord injury in this mouse line (Chapter 4). However, this
does not preclude the possibility of redundancy across several ADAMs causing the
deletion of ADAM21 to show no evident pathological phenotype.
In conclusion, it seems that ADAM21 does not play an essential role in the
development of the mouse, as is the case with ADAM 10 and ADAM 17 or essential in the
recovery after spinal cord injury. However, the function of ADAM21 may be revealed
through combining the ADAM21-deficient line with that of another ADAM deficient line
like was seen with other ADAM deficient mouse lines or by using a different outcome
measure that was not covered in this study. Alternatively, ADAM21 might have both
beneficial and detrimental roles after spinal cord injury which results in the neutral
phenotype of the ADAM21-deficient mice.
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Figure 8. ADAM21 and f3-Galactosidase immunostaining in the adult spinal cord in
sham and spinal cord injured mice.

Transverse sections of the mouse spinal cord were stained with ADAM21 antibody.
ADAM21 immunostaining of the intact spinal cord of wildtype (WT) (A and 8) and
ADAM21-deficient (KO) mouse (D and E): punctated immunostaining is present in the
dorsal horn of wildtype mouse and ADAM21-deficient mouse. Labeling in the
ependymal cells of the central canal is present in wildtype and ADAM21-deficient
mouse , Inset of Band E, respectively. B-Galactosidase immunostaining in the intact
spinal cord of wildtype (WT) (C) and ADAM21-deficient (KO) mouse (F) . 13- Gal
immunostaining in the intact cord shows vessel-like structures (G and H) and in the
injured spinal cord of ADAM21 deficient mice shows possible microglial cell in the white
matter (I and J). WT wildtype mouse and KO ADAM21 deficient mouse. Scale bars
for A, C, D and F, shown in A, represents 20 IJm , for Band E, shown in, represents 20
IJm , and for G-J , shown in G, represents 5 IJm.
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BMS

Baseline
Week 1

+
+

Week 2
Week 3
Week 4
Week 5
Week 6

Baseline

.,.
I

Week 1
Week 2
Week 3
Week 4
Week 5
Week 6

Beam Walk

Hargreaves
(sec)

Tall Flick
(sec)

9.0
4.9
6.0
7.3
6.7
7.1
6.9

± 0.00
± 0.45
± 0.50
± 0.37
± 0.34
± 0.31
± 0.33

24.8 ± 0.09
4.7 ± 1.34
7.5 ± 1.36
9.3 ± 1.30
10.6 ± 1.34
11.8 ± 1.77
11.2 ± 1.55

3.43
2.36
2.73
2.62
2.89
2.86
2.94

± 0.29
± 0.20
± 0.22
± 0.17
± 0.27
± 0.13
± 0.23

1.92 ± 0.08
1.86 ± 0.10
1.69 ± 0.07
1.69 ± 0.07
1.91 ± 0.11
1.78 ± 0.09
1.84 ± 0.12

8.9
6.1
6.9
7.1
7.4
6.8
7.2

± 0.08
± 0.81
± 0.68
± 0.56
± 0.49
± 0.42
± 0.47

24.6 ± 0.28
5.4 ± 1.68
9.2 ± 1.88
11.4 ± 1.54
11.8±2.05
12.6 ± 1.91
12.2 ± 1.94

3.58
2.59
2.83
2.72
2.62
2.60
2.85

± 0.29
± 0.17
± 0.15
± 0.15
± 0.17
± 0.14
± 0.24

1.79 ± 0.08
1.82 ± 0.07
1.81±0.16
1.78 ±0.10
1.85 ± 0.16
1.63 ± 0.10
2.06 ± 0.10

Table 1. Behavioral assessments between ADAM21-deficient mice and wi/dtype
littermates.

There is no statistical significant difference between wildtype and ADAM21-deficient
mice in BMS, Beam Walk, Hargreaves, and Tail Flick. Weeks 1-6 in both wildtype and
ADAM21-deficient mice are significantly different from baseline for BMS, Beam Walk,
and Hargreaves. Scores for BMS and Beam walk in arbitrary units ± SEM and scores
for Hargreaves and Tail Flick are in seconds ± SEM. n =13 and 10 for injured wildtype,
and injured ADAM21-deficient, respectively. Data for shams is not shown. n = 2 and 3
for wildtype and ADAM21-deficient, respectively.
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Sham
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Caudal1rrrn
Rostral + Caudal

1.07
1.16
1.02
1.05

Rostral1rrrn
Epicenter
Caudal 1rrrn
Rostral + Caudal

59,737
34,182
41,409
50,573

56,187
62,772
64,491
60,339
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976
960
1,644
1,310

5,062
4,774
4,452
4.757
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E Epicenter

Injured

-/-

+1+*

1.16±0.071
1.11 ± 0.064
1.09 ± 0.057
1.13±0.044
± 7,200
± 5,180
± 18,496
± 9,068
± 634
± 788
± 920
± 518

-/-

+/+

0.81
0.53
0.81
0.81

± 0.031
± 0.042
± 0.035
± 0.023

129,583 ± 13,644
211,638 ± 20,168
111,492 ± 12,620
120,538 ± 9,283
2,964
2,208
3,086
3,017

± 356
± 1,050
± 460
± 277

0.85
0.59
0.81
0.83
128,803
219,102
116,925
122,551
3,753
2.742
3,588
3,679

± 0.036
± 0.042
± 0.053
± 0.032
± 14,999
± 18,387
± 15,406
± 8,715
± 555
± 362
±474
± 363

Table 2. Histological analyses.
There was no difference between wildtype and ADAM21-deficient mice in spared white
matter, GFAP, and CGRP. The epicenter of injured within each genotype was
significantly different from 1 mm Rostral, 1 mm Caudal, and penumbra (1 mm Rostral +
1 mm Caudal) in all 3 analyses. White matter sparing is in mm2 and GFAP and CGRP
are in IJm2 ± SEM with the exception of wildtype sham due low number of animals. n =
2,3,13 and 10 for sham wildtype, sham ADAM21-deficient, injured wildtype, and injured
ADAM21-deficient, respectively.
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Na'ive
-/-

+/+

T7 13,438 ± 2,980
T8 14,626 ± 2,708
T9 14,550 ± 2,677
T10 15,532 ± 2,559

n=

14,662 ± 963
15,539 ± 1,968
14,622 ± 1,568
13,706 ± 2,074

4

4

Table 3, CGRP immunostaining in naiVe ADAM21-deficient and wiJdtype littermates.
Na"lve levels of CGRP were analyzed to confirm no differences of CGRP at basal levels.
There was no significant difference between wildtype and ADAM21-deficient animals at
2
T7 through T10. All values are given in IJm ± SEM. n=4 in all groups.
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CHAPTER FOUR
COMPREHENSIVE AND QUANTITATIVE METALLOPROTEINASE
GENE ANALYSES REVEAL A REGULATORY ROLE OF ADAM21 IN
NORMAL AND INJURED MOUSE SPINAL CORD
INTRODUCTION
The ADAM proteins belong to the adamalysin family of the metzincin or zincdependent metalloproteinase superfamily which also includes the MMPs. ADAMs have
a disintegrin and metalloproteinase domain, as well as cysteine-rich, EGF-like module,
transmembrane and cytoplasmic signaling domains (Wolfsberg et aI., 1995, Yang et aI.,
2006). The adamalysin subfamilies also include the ADAMTS (containing a
thrombospondin repeat and lacking the EGF-like, transmembrane, and cytoplasmic
domains) and ADAMTSL (lacking the pro-metalloproteinase and disintegrin-like
domains) (Tang and Hong, 1999, Apte, 2009). The catalytic activity of all the
metalloproteinases is inhibited by tissue inhibitors of metalloproteinases (TIMPs) (Brew
and Nagase, 2010).
ADAMs are best known for their role as sheddases in activating cleavagedependent membrane proteins such as Notch and TNFa (Reiss and Saftig, 2009).
MMPs and secreted ADAMTS proteins are best known for extracellular matrix digestion
during tissue remodeling, process outgrowth, and cell migration (Pilcher et aI., 1999,
Curry and Smith, 2006, Amalinei et aI., 2007, Ihara and Nishiwaki, 2007). Another
unique feature of ADAMs is the disintegrin domain which binds integrins (Bigler et aI.,
2000, Evans, 2001). Little is known about the mechanism of action or function of all but
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a few metalloproteinases in general or specifically in the nervous system (Yang et aI.,
2006, Yong et aI., 2007). Several ADAMs have been associated with diseases or
disease pathology such as asthma/inflammation (Van Eerdewegh et aI., 2002, Booth et
aI., 2007, Koller et aI., 2009, Mukhopadhyay et aI., 2010) and neurological diseases
(Gerst et aI., 2000, Barrette et aI., 2010).
In the injured spinal cord, MMP2 and MMP9 were found to be acutely up
regulated in blood vessels, macrophages and astrocytes and to playa predominantly
detrimental role (de Castro et aI., 2000, Noble et aI., 2002, Goussev et aI., 2003, Hsu et
aI., 2006, Zhang et aI., 2011a). Increased MMP12 expression by microglia has a
detrimental role as shown in injured MMP12-/- mice (Wells et aI., 2003). Increased
ADAM8 expression is exclusively localized to endothelial cells after spinal cord injury
and possibly has a role in angiogenesis (Mahoney et aI., 2009). In humans, MMP1,
MMP2, MMP9, and MMP12 are expressed in response to spinal cord injury (Buss et aI.,
2007). Previously, changes in 22 MMPs have been documented up to 5 days following
compression injury in adult mice (Wells et aI., 2003). Others performed an Affymetrix
gene array analysis after a contusive spinal cord injury in adult mice (GEO Profiles
accession GDS2159) which did not include all metalloproteinases and was not
quantitative or verified.
We have shown robust ADAM21 immunostaining in continuously generated
primary olfactory neurons and their growing olfactory bulb axons, as well as in radial glial
lineage cells in the neurogenic subventricular zone of adult mice (Yang et aI., 2005). Its
localization in highly plastic areas of the adult CNS raised the possibility that ADAM21
might play an orchestrating role in repair processes after spinal cord injury. ADAMs
could regulate expression of other metalloproteinases for example through activation of
the Notch or TNFa pathways (Samuel et aI., 2005, Jie et aI., 2009, Bartsch et aI., 2010,
Li et aI., 2011).
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Here, we used a focused comprehensive quantitative Real-Time RT-PCR
(qPCR) gene microarray to document changes in ADAM, ADAMTS, MMP, and TIMP
expression following a contusive spinal cord injury in adult mice. We also determined
the potential role of ADAM21 in regulating other metalloproteinases under normal and
injury conditions using ADAM21 wildtype and homozygous ADAM21-deficient
littermates.

MATERIAL AND METHODS
Animals
A total of 40 mice were used, i.e., adult male and female homozygous ADAM21deficient and wildtype littermates were age and gender matched. They were bred in
house from heterozygous B6.129P2-ADAM21tm1 Dgen/J mice (stock# 006431, Jackson
Laboratory, Bar Harbor, ME, USA; crossbred twice with CS7B/6 mice) and crossbred in
house 3 more times with CS7B/6J mice (stock# 000664, Jackson). The B6.129P2ADAM21tm1Dgen/J (ADAM21-deficient) mouse line was produced by Deltagen, Inc.
which performed a preliminary characterization showing no overt phenotype in multiple
organs and physiological measurements
(http://www.informatics.jax.org/external/ko/deltagen/142.html). All animal procedures
were performed according to University of Louisville Institutional Animal Care and Use
Committee protocols and the National Institutes of Health guidelines.

Spinal cord injury
Mice were anesthetized by an intraperitoneal injection of 0.4 mg/g body weight
Avertin (2,2,2-tribromoethanol in 0.02 ml of 1.2S% 2-methyl-2-butanol in saline, SigmaAldrich, St Louis, MO, USA). A laminectomy was made at T9-T10 spine level and a SO

60

kdyn T9 contusion injury was made using an Infinite Horizons (IH) impactor with steel
stabilizers inserted under the transverse processes one vertebra above and below the
injury in order to stabilize the spine. Sham animals received a T9-T1 0 laminectomy only.
Animals received 0.1 ml of a 20 j.Jg/ml stock of gentamicin (ButlerSchein, Dublin, OH)
and 2 ml saline injected subcutaneously (1 ml before and after injury). After the wound
was sutured in layers, Bacitracin ointment (Qualitest Pharmaceuticals, Huntsville, AI)
was applied to the wound area and the animals recovered on a water circulating heating
pad. Analgesics were given twice daily for first 48 hours of 0.1 ml of a 15 j.Jg/ml stock
solution of buprenorphin (Reckitt Benckise, Hull, England). Analgesia was only given
after the animal was fully awake due to a lethal interaction with Avertin. Manual bladder
expression occurred, as needed, once or twice daily until automatic voiding returned
spontaneously, usually within 7-10 days.

BMS analyses
The mice were tested for hindlimb locomotor function before injury to establish a
baseline, and at 7 days, and 14 days post-injury using the Basso Mouse Scale (BMS)
(Basso et aI., 2006). In short, two people trained and certified by Michelle Basso at
Ohio State University observed mice for 4 minutes in a 47-inch diameter dry pool. The
scores range from 0 - 9, where 0 is completely paralyzed and 9 being normal
coordination, paw placement, truck stability and tail up. Subscores are given when the
animals reach 5 and above on the BMS scale.
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Tissue collection and mRNA measurements by quantitative Real-Time reverse
transcription-PCR (qPCR)
On the day of tissue collection, animals were anesthetized and perfused with icecold PBS. A 4 mm section of spinal cord containing the injury epicenter was freshly
dissected out and flash frozen using liquid nitrogen until further processing. Total RNA
was isolated using a commercial kit (Cat #: AM1924, Ambion, Austin, TX). In short, 1 I-Ig
of DNAse was added to RNA (Cat #: 18068-015, Invitrogen, Carlsbad, CA) and used as
templates for reverse transcription, which included 1 1-11 of a 0.5 1-1 g/I-I I random primers
(Cat# : C 1181 ,Promega, Madison, WI), 1 I-Ig total RNA, 5 1-11 of 5x buffer, 1.25 1-11 of 10
mM dNTP mix, 2.25 1-11 RNAse free water, and 1 1-11 (200 units) of Moloney Murine
Leukemia Virus Reverse Transcription (M-MLV RT, Cat #: M170, Promega, Madison,
WI) and heated at 3rC for 1 hr. The qPCR was performed using TaqMan® Universal
PCR Master Mix (Part Number: 4304437), TaqMan® Array Micro Fluidic Cards, Format
96-a (Part Number: 4342259) and primer sets (see Table 4) from Applied Biosystems,
Carlsbad, CA. All cards were run on an Applied Biosystems® 7900HT Fast Real-Time
PCR System. Data was analyzed using the SDS 2.1 Relative Quantification software by
the MCT/comparative CT method. All samples were normalized to GAPDH; sham
spinal cord CT values of the same genotype were used as the calibrator. Statistical
analyses were performed with the Student's unpaired t-test using Excel software for
ADAM21-deficient sham versus wildtype sham (Microsoft, Redmond, WA). For all other
comparisons, two-way ANOVA with Tukey post-hoc was used to compare genotype and
changes over time. A value of p S 0.05 was considered statistically significant.
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Housekeeping genes and negative control
There were 4 housekeeping genes included on the qPCR array. They included
hypoxanthine phosphoribosyl transferase 1 '(Hprt1), Beta-glucuronidase (Gusb),
Glyceraldehyde 3-phosphate dehydrogenase (GapDH), and 1BS ribosomal RNA (1BS).
Of these housekeeping genes, only two had steady CT values among all samples:
GapDH and 1BS. However, GapDH was the least variable after spinal cord injury at 7
and 14 days and thus used for normalization. In addition, our negative control for the
qPCR array was human CNTF and was undetectable on all arrays.

RESULTS
Temporal mRNA profile in wildtype littermates after spinal cord injury
Major changes (more than two-fold) in gene expression profile occurred in 19
metalloproteinase genes following spinal cord injury in wildtype mice (Figure 9; Table 5).
Seventeen metalloproteinases were increased more than two-fold at 7 and/or 14 days.
Of these, ADAMB, ADAM33, and MMP12 were up regulated more than 10-fold
compared to the uninjured sham mice at either or both day 7 and 14 post-injury. Only 3
genes were decreased more than two-fold following injury, i.e., ADAM23, ADAMTS17,
and MMP17. Surprisingly, ADAM21 was not detectable using the Mm01309314_m1
assay which spans exon1 and exon2. However, in a separate qPCR analysis of the
same RNA ADAM21 was detectable using the Mm004B0375_s1 assay which measures
onlyexon2. There was no change in the expression level of ADAM21 after injury.
We also measured expression levels of the 4 known endogenous
metalloproteinase inhibitors. Only TIMP1 expression changed more than two-fold,
increasing by almost 20-fold following spinal cord injury compared to sham. Also
included were a few potential substrates of ADAMs to support future investigations into
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their potential interactions. Thus, as expected, TNFa was highly up regulated at 7 and
14 days after injury. Alpha-2 macroglobulin (A2m) was also increased at 14 days
whereas alpha-synuclein (SNCA) showed a large decrease at 7 and 14 days post-injury
compared to sham. Alpha-1 antitrypsin (Serpina1e) was not detectable in either sham or
injured spinal cord.

Sham-operated ADAM21-deficient mice have few changes compared to wild-type
littermates
Under normal conditions, only one gene, ADAMTS16, was significantly higher
(1.7 fold) in ADAM21-deficient than in wild-type littermates. However, 4 genes,
ADAM19, MMP17, MMP24, and TIMP4 were found to be significantly decreased in the
ADAM21-deficient sham-operated mice.
Surprisingly, ADAM21-deficient mice had an ADAM21 transcript detectable by
the Mm00480375_s1 assay (beyond the deletion-insertion locus) which was confirmed
by endpoint PCR of different regions of the 3' ADAM21 transcript (data not shown). This
transcript was increased 3-fold in sham animals. However, we confirmed that the
LacZ/Neo cassette was inserted into the ADAM21 gene in the middle of the
metalioproteinase domain and prior to the catalytic site (data not shown). A theoretical
in-frame ADAM21 start codon would make this a metalioprotease-nuli aberrant
transcript.

ADAM21-deficient mice have reduced expression levels of metalloproteinases
after spinal cord injury
In ADAM21-deficient mice, mRNA levels of 4 metalioproteinase genes, ADAM8,
ADAM33, ADAMTS14, and MMP12 were more than 2 fold lower than their wildtype
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littermates following spinal cord injury. Of these, ADAM8, ADAM33, and MMMP12, were
decreased by more than 10 fold compared to their injured wild-type littermates. Two
metalloproteinase genes (MMP10, MMP27) were detected at all time points in ADAM21deficient mice, but not detectable at any time point of their wild-type littermates.
ADAM28 expression was not seen in wild-type mice, even after spinal cord injury but
was seen in some sham-operated ADAM21-deficient mice (4 out of 7) and some injured
mice after 14 days (2 out of 6).
TIMP expression levels were not found to be different in injured ADAM21deficient mice. Of the metalloproteinase substrates measured here, only TNFa had
expression levels more than two fold different in injured ADAM21-deficient mice
compared to injured wild-type littermates. In fact, TNFa expression levels in the injured
ADAM21-deficient mice were 10-fold less than that seen in injured wild-type mice.
Only 8 metalloproteinase genes had no detectable expression in sham or injured
mice irrespective of the presence or absence of ADAM21 or spinal cord injury. These
included ADAM2, ADAM26b, ADAM34, ADAM36, MMP1a, MMP1b, MMP20, and
MMP21. There were 15 metalloproteinases present in only a few samples and therefore
could not be statistically analyzed in this array. These included ADAM3, ADAM5,
ADAM6A1ADAM6B, ADAM7, ADAM24, ADAM25, ADAM26A, ADAM28, ADAM29,
ADAM30, ADAM38, ADAM39, ADAMDEC1, ADAMTS13, and MMP7.

Locomotor function
As expected for a moderate injury, the BMS scores in the wildtype mice decreased to
4.1 and 3.7 at 7 and 14 days post injury, respectively. Despite the striking differences in
gene expression levels, there were no significant differences between genotypes in the
baseline or post-surgery BMS scores of sham-operated mice or after a T9 contusive
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spinal cord injury at 7 or 14 days (Figure 10). Additionally, at 14 days post-injury only 3
out of 13 mice had high enough BMS scores to have a subscore, 2 of 7 animals were
wildtype, and 1 of 6 was an ADAM21-deficient mouse which was not significantly
different.

DISCUSSION
The ADAM21-deficient mouse results suggest that ADAM21 normally upregulates the expression of a substantial number of metalloproteinase genes following
spinal cord injury. This is somewhat surprising as one of the greatest hurdles using
knockout mice is the frequent redundancy or overlap of function between proteins due to
their high homology within the domain structures and sheer number of
metalloproteinases. Thus, we propose that ADAM21 is an important regulator after
spinal cord injury. Of particular interest, a cluster of genes known for their role in
inflammation (ADAM8, ADAM12, ADAM33, MMP12, TNFa (King et aL, 2004, Dehmel et
aL, 2007, Jie et aL, 2009, Koller et aL, 2009, Mukhopadhyay et aL, 2010, Parameswaran
and Patial, 2010)), exhibited a robust increase in injured wild type littermates, which was
significantly attenuated in injured ADAM21-deficient mice. In addition, ADAM8,
ADAM12, and ADAM33 are within the same phylogenetic group (Hooper et aL, 2005).
This inflammatory gene cluster seems unique in that ADAM8, ADAM12, ADAM33,
MMP12, and TNFa are the only ones so far that have been linked to asthma (Shapiro
and Owen, 2002, Van Eerdewegh et aL, 2002, Holgate et aL, 2004, Haitchi et aL, 2005,
Berry et aL, 2007, Koller et aL, 2009, Holgate, 2010, Mukhopadhyay et aL, 2010,
Paulissen et aL, 2011). Under normal conditions (sham-operated), these genes were
not changed in ADAM21-deficient mice. This raises the possibility that ADAM21 plays a
central role in inflammatory responses under pathological conditions. However, only 6
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papers have been published so far on ADAM21 (Hooft van Huijsduijnen, 1998,
Poindexter et aL, 1999, Liu and Smith, 2000, Seldin et aL, 2000, Yang et aL, 2005, Yi et
aL, 2010), mostly describing its presence in the testis, and its functional roles in different
organs remains to be investigated.
It remains to be determined how ADAM21 would regulate the expression of the
other metalloproteinase genes. The ADAM21-deficient mice contain a Lac-z gene
insertion within the metalloproteinase domain with a potential metalloproteinase-dead
read-through to the end of the gene. This suggests that the regulation of the other
genes is normally through the metalloproteinase domain possibly by its sheddase
activity to release growth factors or other cleavage-dependent proteins. Moreover,
ADAM21 does not have sequences in its C-terminus that are known to allow binding of
intracellular signaling molecules. The absence of ADAM21 after spinal cord injury
caused a dramatic decrease in TNFa gene expression levels possibly because of its
normal sheddase activity on CD14 and/or Notch. CD14, expressed mainly on
macrophages, co-signals through TLR leading to an increase in Notch and NF-KB
(Beutler, 2000, Monsalve et aL, 2009). In addition to TNFa expression, the Notch
signaling pathway has been linked to ADAM 12 expression (Li et al., 2011) and indirectly
linked to the expression of ADAM8, ADAM33, and MMP12 through increases in
downstream targets of Notch such as IL-4 and AP-1 (King et aL, 2004, Samuel et aL,
2005, Tanaka et aL, 2006, Jie et aL, 2009). The decrease seen in ADAM8 in the
absence of ADAM21 was not decreased to the same degree as that of the other genes
in the inflammatory cluster. This could be the result of TNFa induced up regulation in
ADAM8 (Bartsch et aL, 2010). ADAM8 then cleaves TNFaR1 which can then bind
soluble TNFa, thereby desensitizing a cell to the action of TNFa, and causing an
apparent feedback loop (Schlomann et aL, 2000, Bartsch et aL, 2010).
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Of note was the finding that ADAM21 deletion did not affect expression of the
ADAMTS family members, except for ADAMTS19, following spinal cord injury. The
expression levels of some ADAMTSs have been shown to be regulated by induction by
IL-1 or down regulation by hypermethylation (Kuno et aI., 1997, Wagstaff et aI., 2011).
Our unpublished data (Chapter 3) suggest that ADAM21 in the injured spinal cord is
located in cells resembling microglia at the injury site. Astrocytes and microglia are
known to be rapid responders to spinal cord injury and to be intricately involved in
initiating inflammation (Brambilla et aI., 2005, Kigerl et aI., 2009, Loane and Byrnes,
2010, Pineau et aI., 2010). Thus, astrocytic and microglial ADAM21 is the most likely
candidate for playing a central orchestrating role in the secondary responses to injury.
As with other ADAMs which have enzymatic, adhesive and other signaling properties,
the physiological targets and mechanism of action of ADAM21 remains to be
determined.
We did not observe significant differences in the locomotor function of the
ADAM21-deficient mice compared to their wild-type littermates despite the major
differences in levels of inflammatory gene expression. A contusive spinal cord injury
quickly evolves and progresses into a secondary injury due to inflammation, degradation
of both blood vessels and axons and ultimately leading to increased cell death (Hall and
Springer, 2004, Hagg and Oudega, 2006, Bramlett and Dietrich, 2007, Fassbender et
aI., 2011 b). The extent of inflammation is thought to predict the functional outcomes and
experimental anti-inflammatory treatments are beneficial (Popovich et aI., 1999, Weaver
et aI., 2005, Gonzalez et aI., 2007). On the other hand, certain aspects of acute
inflammation are thought to be beneficial (Barrette et aI., 2007, Kigerl et aI., 2009). For
example, macrophages remove toxic debris from the injured spinal cord (Popovich and
Jones, 2003). The role of the individual ADAMs has been proposed to be both beneficial
and detrimental (Yong, 2005, Rivera et aI., 2010). For example, although ADAM10 and
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ADAM 17 promote pro-inflammatory signaling events (including TNFo shedding), they
also have protective effects in the injured nervous system (including shedding of amyloid
precursor protein, N-cadherin, and Ephrins) (Pruessmeyer and Ludwig, 2009). Further
research into the effects ADAM21 has on regulating other proteins involved in
inflammation following a spinal cord injury could elucidate the differential processes
involved in the inflammatory response.
In the current study no apparent phenotype was seen in the na"ive (see also
http://www.informatics.jax.org/external/ko/deltagen/142.html) or injured ADAM21deficient mouse, raising the possibility that one of the other metalloproteinases had
compensated for the lack of ADAM21. In sham animals, there were only two genes with
significant increases in mRNA levels. ADAM28 was only detected in ADAM21-deficient
mice under normal or injury conditions, but only in a subset of mice. The presence or
absence of ADAM28 did not predict the expression levels of the genes regulated by the
absence of ADAM21. This suggests that ADAM28 had not compensated for the lack of
ADAM21. ADAMTS16 showed an increase (70%) in ADAM21-deficient mice under
sham conditions. It has been linked to a decrease in cell proliferation and migration
when overexpressed in chondrocyte cell lines (Surridge et aI., 2009). After spinal cord
injury, ADAMTS16 was not changed in wild-type mice but was reduced to 63% (p<0.05,
Table 5) in the ADAM21-deficient mice. This suggests that ADAMTS16 did not
compensate under injury conditions, which leads us to believe that under normal
conditions, it did not compensate in the absence of ADAM21.
In the wild-type mouse, most of the changes following spinal cord injury involved
an increase in expression, suggesting that the metalloproteinases play an important role
in the responses to injury. Our results are similar to the Affymetrix Mouse Genome 430
2.0 Array data from injured wild-type C57BL6 mice (GEO Profiles accession GDS2159).
For example, ADAM8, ADAM12, ADAM33, MMP12, which we showed all have an
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increased expression of more than 10 fold, was 11,163, 435, 298, respectively. Our
results also confirm reported increases in ADAM8 (Mahoney et aI., 2009), MMP2
(Goussev et aI., 2003), MMP10, MMP11, MMP12 and MMP13 (Wells et aI., 2003), and
MMP14 (Mahoney et aI., 2009). There are some differences in changes of 6 genes,
such as MMP3 and MMP8, at 7 days compared to with the other TaqMan microarray
analysis 5 days post-injury (Wells et aI., 2003) most likely because of the different type
of injury. ADAM10 and ADAM17, both associated with sheddase activity on substrates
such as amyloid precursor protein, Notch, and TNFa in the brain (Asai et aI., 2003,
Pruessmeyer and Ludwig, 2009), increased by around 2-fold after spinal cord injury
suggesting that they may play similar roles under that pathological condition.
Of particular note, MMP10 expression was "turned on" at 7 and 14 days post
injury. MMP10, also known as Stromelysin-2 or SL-2, has been associated with cell
migration (Pilcher et aI., 1999, Krampert et aI., 2004). In spinal cord injury, MMP10, like
ADAM8, seems to playa role in angiogenesis (Heo et aI., 2010). Here, MMP27 was
another newly expressed gene after spinal cord injury. To date, not much is known
about MMP27 other than expression profiles (Bernal et aI., 2005). We suggest that
MMP10 and MMP27 warrant further study as to their role after spinal cord injury.
Despite the many members, most metalloproteinases were expressed at some point
before or following spinal cord injury suggesting that this is a very important class of
proteins in neural injury.
We also measured the expression of the TIMPs which are natural
metalloproteinase inhibitors (Brew and Nagase, 2010). The main response was in
TIMP1, showing an almost 20 fold increase following spinal cord injury in wild type mice.
This increase would predominantly counteract MMPs (Brew and Nagase, 2010). TIMP1
has a more restricted inhibitory range than the other 3 TIMPs, showing low affinity for
MT-MMPs, MMP14, MMP16, MMP19, and MMP24, and is present in plastic regions of
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the adult eNS (Rivera et aL, 1997, Fager and Jaworski, 2000, Hornebeck et aL, 2005,
Nagase and Murphy, 2008). However, TIMP-1 has stronger affinity for MMP3 and
MMP7 than other TIMPs (Hamze et aL, 2007). Thus, it could play similar roles in the
injured spinal cord. The TIMP1 levels were also increased in the injured ADAM21deficient mice although at only 60-70% of wild type. How this would affect the activity of
the metalloproteinases to affect differential function in the ADAM21-deficient mice
remains to be determined. The increase in TIMP1 expression seen in the present study
seems to correlate to its proposed involvement in glial scar formation (Ahmed et aL,
2005). However, TIMP1 may also act through a mechanism independent of
metalloproteinase inhibition (Ogier et aL, 2005, Ogier et aL, 2006). TIMP2 was
increased more in the injured ADAM21-deficient mice than in the wild type mice. In
humans, TIMP2 has inhibitory actions on all MMPs and ADAM12 (Jacobsen et aL, 2008,
Brew and Nagase, 2010). TIMP3 is generally thought of as an ADAM and ADAMTS
inhibitor in addition to its inhibition of MMPs (Amour et aL, 2000, Hashimoto et aL, 2001,
Kashiwagi et aI., 2001, Wang et aL, 2006, Wisniewska et aL, 2008).
In conclusion, our data suggest that ADAM21 plays significant role in regulating
expression of other metalloproteinases perhaps in a nodal manner, as ADAM21 appears
to be an important regulator of a cluster of genes associated with the immune response
to injury. Our comprehensive quantitative gene analyses also provide a platform for
further study into the role of metalloproteinases after spinal cord injury.
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Gene
ADAM1a
ADAM1b
ADAM2
ADAM3
ADAM4
ADAM4b
ADAM5
ADAM6aJADAM6b
ADAM7
ADAM8
ADAM9
ADAM10
ADAM11
ADAM12
ADAM15
ADAM17
ADAM18
ADAM19
ADAM21
ADAM22
ADAM23
ADAM24
ADAM25
ADAM26a
ADAM26b
ADAM28
ADAM29
ADAM30
ADAM32
ADAM33
ADAM34
ADAM36
ADAM38

Inventoried

Ref Seq #

Assa~ID

Mm02581738 s 1
Mm00844462 s1
Mm00802061 m1
Mm00456453 m1
Mm00550163 s1
MmO 1302735 s 1
Mm00801437 m1
Mm00558079_s1
Mm00475743 m1
Mm00545745 m1
Mm00475763 m1
Mm00545742 m1
Mm00477288 m1
Mm00475719 m1
Mm00477318 m1
Mm01231071 m1
Mm00438562 m1
Mm00477337 m1
Mm01309314 m1
Mm01316488 m1
Mm00478613 m1
Mm00438567 s1
Mm00785241 s1
Mm00783690 s1
Mm01609627 m1
Mm00456637 m1
Mm01353952_s1
Mm00810549 s 1
Mm00462905 m1
Mm00459691 m1
Mm01545315 m1
Mm03015167 s1
Mm02342382 s1

NM 172126
NM 172125
NM 009618
NM 009619
NM 009620
NM 001038995
NM 007401
NM_174885/NM_ 001009545
NM 007402
NM 007403
NM 007404
NM 007399
NM 009613
NM 007400
NM 009614
NM 009615
NM 010084
NM 009616
NM 020330
NM 001007220
NM 011780
NM 010086
NM 011781
NM 010085
NM 001009547
NM 183366
NM 175939
NM 027665
NM 153397
NM 033615
NM 145745
NM 001025240
NM 001009548

Table 4. Genes analyzed.
Assay and reference sequence numbers for all the genes that were analyzed by in the
Applied Biosystems microfluidic gene Taqman array plates. * = assays that were used
in an additional analysis which were performed in triplicate with GAPDH as the reference
assay. Mm Mus musculus, Hs Homo sapiens.

=

=
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Gene
ADAM39
ADAMDEC1
ADAMTS1
ADAMTS2
ADAMTS3
ADAMTS4
ADAMTS5
ADAMTS6
ADAMTS7
ADAMTS8
ADAMTS9
ADAMTS10
ADAMTS12
ADAMTS13
ADAMTS14
ADAMTS15
ADAMTS16
ADAMTS17
ADAMTS18
ADAMTS19
ADAMTS20
ADAMTSL1
ADAMTSL2
ADAMTSL3
ADAMTSL4
ADAMTSL5
MMP1a
MMP1b
MMP2
MMP3
MMP7
MMP8
MMP9

Inventoried
Assa~ID

Mm02581333 s 1
Mm00546409 m1
Mm00477355 m1
Mm00805171 m1
Mm00625880 m1
Mm00556068 m1
Mm00478620 m1
Mm00615566 m1
Mm01239067 m1
Mm00479220 m1
Mm00614433 m1
Mm00553926 m1
Mm00615603 m1
Mm01218030_g1
Mm01169235 m1
Mm01176187 m1
Mm00468144 m1
Mm01318698 m1
Mm00552621 m1
Mm00558559 m1
Mm00724059 m1
Mm00553186 m1
Mm01326794 m1
Mm01312414 m1
Mm00523242 m1
Mm00481701 m1
Mm00473485 m1
Mm00473493-1J1
Mm00439505 m1
Mm00440295 m1
Mm00487724 m1
Mm00772335 m1
Mm00600164..91

Ref Seq #
NM_001025380
NM 021475
NM_009621
NM 175643
NM_001081401
NM 172845
NM 011782
NM_001081020
NM_001003911
NM_013906
NM 175314
NM 172619
NM_175501
NM_001001322
NM_001081127
NM_001024139
NM_172053
NM_ 001033877
NM 172466
NM_175506
NM_177431
NM_172542
NM_029981
XM 194370
NM 144899
NM_025629
NM 032006
NM_032007
NM_008610
NM_010809
NM_010810
NM_008611
NM 013599

Table 4 Continued
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Gene

Inventoried
Assa~ID

Ref5eq #

TNFa
185
Gusb
Hprt1
GapDH
CNTF

Mm01168399 m1
Mm00485048 m1
Mm00500554 m1
Mm01168713 m1
Mm01318966 m1
Mm00485062 m1
Mm00490659 m1
Mm00449292 m1
Mm00491300 m1
Mm00600244 m1
Mm00461814 m1
Mm00488768 m1
Mm00487721 m1
Mm01309189 m1
Mm01169173 m1
Mm00712992 m1
Mm00441818 m1
Mm00441825 m1
Mm00441827 m1
Mm00446568 m1
Mm00833655_m1
Mm01188700 m1
Mm00438851 m1
Mm00558642 m1
Mm00443258 m1
H599999901 51
Mm00446953 m1
Mm00446968 m1
Mm99999915_91
H500173456 m1

NM 019471
NM_008606
NM_008605
NM_008607
NM_008608
NM 008609
NM 019724
NM_011846
NM 021412
NM 013903
NM_152944
NM_011985
NM_010808
NM_001033339
NM_001030289
NM 172797
NM_011593
NM_011594
NM_011595
NM_080639
NM_009247
NM_001042451
NM_010169.3
NM 175628
NM 013693.2
X03205.1
NM_010368
NM_013556
NM_008084
NM_000614.3

ADAM9*
ADAM21*

Mm00475761 m1
Mm00480375 51

NM 007404
NM 020330

MMP10
MMP11
MMP12
MMP13
MMP14
MMP15
MMP16
MMP17
MMP19
MMP20
MMP21
MMP23
MMP24
MMP25
MMP27
MMP28
TIMP1
TIMP2
TIMP3
TIMP4
5erpina1 E
5nca
F2R

A2m

Table 4 Continued

74

2.-----------------& 1.5 t - - - - - - - - ----i----

i

6

3

t

2

2.5

I t -__-=~--~~---

61 .5

~ 05 + - - - - - - - - -

~ 1
IL

_

WT

~O

_

&1 .5

is

I

1

f

~
IL 0.5
0

Sham
_WT ~O

.
-...
7 day

~

+

0.5

~O

14 day

Sham

• Sham KOvs Sham WT

WT ~O

7~y

14~

• Sham KO vs Sham WT

Adilm9- Mm00475761_m1

2,----------i

WT

.lc

1

0

7 day

Sham

• Sham KO vs Sham WT

J

~

. /1

T

o

14 day

Sham

~

./'

0.5

O ~----~----~--~

1

&1.5

2

150 , - - - - - - - - - -

&100 t - - - - --i-- - --::i-i

6

50 f - - - -:6I''-±-- - - -

3,------------2.5 t - - - --y-- ---rt t:::==:~f;
I ~--~t=
~

2
61 .5 t-

~ o t-__~~---~~~

J 1 +-~...~------'---

-50 '-------------Sham
14d3Y

O ~---~--~-~
Sham
14 day

14 day

~O

• Sham KO vs Sham WT

0.5

• ShamKOvsShamWT

_

t----------

WT

~O

• Sham KOvsShamWT

Adilm1O-MmOO545742_m1

~ ,------------

& 2

t-----~
-r----

1.4
12
1
0.8

&

i 1.5 t -T
I. -::2
.JIIf'::...~~~r- 6
6 I t--~.~
~------ - :v 0.6
i

J0.5 +-_T_________

I
./T

.I.

.

!""'oo..

........

~~

T

~0.4

4
3.5
3
2.5

&
6 2
i

i

IL

02

o

O ~--~--~-~
14 day
Sham
_

WT

~O

_

2,-------------

WT

&
6 2
i

~

1.5
1

IL

0.5

_

WT

~O

14 day
• Sham KO ys Sham WT

• ShamKOvsShamWT

Sham

_

I

-'f
./"
V"

WT

WT

7~

14d3Y

~O

• Sham KO vs Sham WT

t

1

1 .-"""":
I

2.5

2

6 1.5

~

IL

T

1

0.5

. KO -sham KOvs Sham WT

t

o

14 day

Sham

_

.I'

3

1

o

O +----~--~-~

Sham

~O

4

3.5
3
2.5

VT'

o

14 day

Sham

• ShamKOvsShamWT

l .5
1
0.5

....
........ ,

~

Sham

_

WT

. KO

~ham

KO

YS

Sham WT

Figure 9_ Gene profile of aI/ genes that evoked a consistent signal among the samples
fol/owing a T9 contusive spinal cord injury.
Each graph displays the changes in gene expression in wildtype (WT) or ADAM21deficient (KO) after injury at 7 and 14 days. In addition, the black triangle signifies the
ratio in gene expression between the ADAM21 -deficient and the wildtype mice in the
absence of an injury. All values shown are average fold change ± SEM. n= 8, 8, and 7
for ADAM21-deficient sham , 7 days , and 14 days post injury, respectively and n= 6, 4,
and 7 for wildtype sham , 7 days, and 14 days post injury, respectively.
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Gene

ADAM1a
ADAM1b
ADAM2
ADAM3*
ADAM4
ADAM4b
ADAMS*
ADAM6aJADAM6b*
ADAM7*
ADAMS
ADAM9
ADAM10
ADAM11
ADAM12
ADAM1S
ADAM17
ADAM1S
ADAM19
ADAM21
ADAM22
ADAM23
ADAM24*
ADAM25*
ADAM26a*
ADAM26b
ADAM2S*
ADAM29*
ADAM30*
ADAM32
ADAM33
ADAM34
ADAM36
ADAM38*
ADAM39*
ADAMDEC1*

KO sham vs
WT sham

WT 7 day vs
WT sham

Fold

-value

Fold

-value

Fold

1.07
1.83

0.625
0.242

0.77
0.74

0.379
NA

-0.10
-0.24

NO
NO

NO
NO

NO
NO

NO
NO

0.173
0.805

0.06
-0.14

NS
NA

0.07

NO
NO
NO

NO
NO
NO

NO
NO
NO

NO
NO
NA
NA
NO
NO
NO

NO
NO

0.71
0.91

NO
NO
0.77

NO
NO

NO
NO

NO
NO

5.15
1.28
1.24
0.78
1.44
1.24
1.18
0.85
0.77
3.15
1.25
0.77

0.142
0.264
0.168
0.060
0.399
0.223
0.336

73.67
1.96
1.75
0.56
2.69
1.55
2.40
1.00
0.77
1.33
1.40

NA

-0.24
0.23
-1.47
-0.22
-0.16
-0.32
0.29
-0.16
-0.03
0.26

NO
NO
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO

0.98
3.11

0.966
0.121

0.75
8.42

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO

0.931
0.144

1.06

NO
NO
NA
NA
NO
NO

NA
0.078
NA
NA

WT 14 day vs
WT sham

NO

NO
NO

NO
NO

0.76
1.21

NA
NA

0.83
0.92

NO
NO
NO

NO
NO

NO
NO
NO

90.33
2.29
1.56
0.74
3.23
1.59
3.05
1.44
0.75
1.07
0.98

NA
NA

.000
NO
NO
NO
NO
NO
NO
NO
NA
NO
NO
NO
NO
NO

KO 7 day vs
KO sham

NO
NO
NO
NO
NO
NO
NO

1.52
15.69
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO
NA

35.96
1.74
1.40
0.60
2.83
1.25
2.53
0.91
1.17
0.80
0.71
0.54

NS

NO
NO
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO
NA

0.98
1.74

NO
NO
NO
NO
NO

NO
NO
NA
NA
NO
NO
NO

NO
NO
NO
NO
NO

KO 14 day vs
KO sham

NO
NO

1.51
1.28
NO
NO
NO

17.53
1.68
1.32
0.97
1.76
1.37
2.89
1.12
1.04
0.91
0.95
0.70
NO
NO
NO
NO
NO
NO
NO

NS

1.42
4.79

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO

KO 7 day vs
WT 7 day

KO 14 day vs
WT 14 day
-value

-0.59

NA
NA

NA
NO
NO

NS

0.040
0.249
0.978
0.508
0.066

0.003
NA
NA

NA
NA
NO
NO
NO
NO
NO
NO
NO
NA

-0.35
0.04
0.13
-0.30
0.13
-0.10
0.40
-0.53
-0.69
0.05

NA
NA
NA

0.23

NA
NA
NO
NO
NO
NO
NO
NO
NO
NA

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO

-0.11

NS
NO
NO
NO
NO
NO

NA
NA
NA
NA

NA
NS
NA
NA
NO
NO
NO
NO
NO
NO
NO
NA
~.010

NO
NO
NO
NO
NO

NO
NO
NO
NO
NO

Table 5. Fold changes and p-values of the data in Figure 9.
Genes are grouped in numerical order by different subfamilies of metalloproteinases ,
metalloproteinase inhibitors, metalloproteinase substrates, housekeeping/reference
genes and the negative control , human CNTF. Increases greater than 2-fold are
highlighted in yellow, decreases greater than 2-fold are highlighted in red and statistically
significant p-values (less than 0.05) are highlighted in green. Significance was
determined by changes with a p < 0.05 calculated by an unpaired Student's t-test. n= 8,
8, and 7 for AOAM21-deficient sham, 7 days, and 14 days post injury, respectively and
n= 6, 4, and 7 for wildtype sham, 7 days, and 14 days post injury, respectively. Asterisks
= genes that had expression in only a few samples. NO = Not detectable, NA = Not
applicable due to lack of significance in ANOVA, and NS = Not significant
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Gene

ADAMTS1
ADAMTS2
ADAMTS3
ADAMTS4
ADAMTS5
ADAMTS6
ADAMTS7
ADAMTS8
ADAMTS9
ADAMTS10
ADAMTS12
ADAMTS13*
ADAMTS14
ADAMTS15
ADAMTS16
ADAMTS17
ADAMTS18
ADAMTS19
ADAMTS20
ADAMTSL1
ADAMTSL2
ADAMTSL3
ADAMTSL4
ADAMTSL5
MMP1a
MMP1b
MMP2
MMP3
MMP7*
MMP8
MMP9
MMP10
MMP11
MMP12
MMP13
MMP14
MMP15
MMP16
MMP17
MMP19
MMP20
MMP21
MMP23
MMP24
MMP25
MMP27
MMP28

KO shamvs
WTsham

1.11
1.08
0.91
1.12
3.02
0.93
1.05
1.31
NO
2.30

WT 7 day vs
WT sham

WT 14 day vs
WT sham

0.227
0.677
0.755
0.499
0.054
0.632
0.632
0.259
NO
0.190

KO 7 day vs
KO sham

NA
NA

0.026
NO
1.76
1.94
0.63
0.58
0.89
0.96

0.85
0.83
1.06
0.98
0.80
0.97
0.75

0.782
0.453
0.779
0.087

3.19
1.06
1. 14
0.70

0.360
1.000
0.878
0.143

f\I)

NO
2.30
1.03
NO
1.51
18.68
0.66
1.07
0.94
0.98

NO
NO
0.380
0.162
NO
0.143
0.957
NO
0.245
0.359
0.948
0.673
0.640
0.816

NO
NO
NA
NS
NO

f\I)

1.49
0.84
NO
6.78
0.76
NO
3.83
2.97
3.02
0.72
1.09
2.99
NO

NO
1.27
0.56
2.04
NO
0.93

1.42
0.65
NO
NO
1.92
8.16
NO
3.70
0.53
NO

0.054
NO
NO
NA

<.060
NO
0.087

0.140
0.763
0.055
NO
NO
0.993
0.059
NA
NA
NS

NO
NO
1.57
0.61
1.51
NO
1.55

NO
NO
0.514
0.069
NA
NA
NS
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0.80

NO
0.517
0.152
NA

0.022
NA
NA

KO 14 day vs
KO sham

1.09
1.11
0.69
2.22
1.38
3.80
NO
0.94
3.37
0.56
0.76
0.84

NO
NO
2.71
24.81
NO
2.98
0.77
0.92
3.08
20.87
3.85
2.78
0.78

0.40
-0.17
0.22
0.05
-0.34
-0.11

NA
NS
NA
NA
NA
NA

-0.05
0.39
0.51
-0.02
0.10

NA
NA
NS
NA
NA

-0.03
1.94
0.56
0.10
0.29

NO
NO
1.57
0.02

NO
NO
NA
NS
NO
NA
NA

NO
NO
0.79
16.65
NO
-0.72
0.24

NA
NA
NA
NA

NA
NA
NO

<
NA
0.263
NA

NO
NO
NA

KO 14 day vs
WT14day

-0.03
0.06
0.12
0.48
-0.30
-1.24
0.38
0.10
-1.42
NO
-0.89
0.87
-0.90
0.27
0.21
-0.60
0.55

-0.07
0.08
-0.26
-0.80
-1.55
0.53
0.02
1.02
NO

0.757
0.376

NO
NO
NO
NO
3.06
NA
0.86
NS
NO
NO
2.71 0.563
0.98
NA
1.70
NA
4.08 0.003
15.74
NS
4.22
NA
3.68 0.003
0.71 0.097
1.13
0.57
4.48
NO
NO
3.24
0.66
1.44
1.56
2.19

K07dayvs
WT7day

-value
NA
NS
NA
NA
NA
NA

NA
NA
NO
NS
NA

<0.010
NA
NA
NA
NA
NA
NA

<0.060
NA
NA
NO
NO
NA

<0.010
NO
NA
NA
NA
NA

<0.010
-0.01
0.04
0.17
1.49
NO
NO
0.10
-0.60
NA
1.26

NA
NA
NA
NA
NA
NO
NO
NA
NA
NA

<0.010

0.15
0.04
0.32
0.18
NO
NO
0.99
0.21
-0.06
NA
1.55

NA
NA
NA
NA
NA
NA
NO
NO
NS
NA
NA
NA
NS

Gene

TlMP1
TlMP2
TIMP3
TIMP4

KO shamvs
WTsham

WT7 dayvs
WTsham

WT 14 day vs
WTsham

K07 dayvs KO 14 day vs
KO sham
KO sham

KO 14 dayvs
WT 14 day

Fold p-value

Fold

-value

Fold

1.40
0.87

12.99
2.17
1.41
1.67

(1;(101
0.003

1.16
0.53
0.27
0.12

-value
NA
NA
NA
NA

-value
NA
NA
NA
NA

NO

NO

NO

0.05
-0.02
0.02

NA
NA

NA
NA

0.239
0.601

0 .94 ~
0.89 0.046

1.10
1.06

0.061

5erpina1E
5nca
F2R
A2m
TNFa

NO

NO

NO

0.006
NO

0.78
0.97
1.33
4.21

0.349
0.805
0.241
0.082

0.84

0.372

185
Gusb
Hprt1

1.20
2.08
0.86

0.143
0.526
0.194

I NO

NO
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Figure 10. Locomotor function in wi/dtype and ADAM21 -deficient mice did not differ
before or after spinal cord injury.
The BMS scores were not significantly different between genotypes at baseline or after
injury. As expected at 7 and 14 days post-injury the BMS scores are decreased
significantly from that of shams . All values are reported as average BMS score ± SEM .
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CHAPTER FIVE
DISCUSSION

General
Summary of findings in Chapter 2

In Chapter 2, we examined the possibility that stimulation of the 5HT1A
receptor causes a decrease in cAMP resulting in an increase in CNTF leading to
an increase in neurogenesis as seen with stimulation of the 02 receptor (Yang et
aI., 2008). As shown by others, we saw an induction of neurogenesis in the SGZ
of rats after stimulation of the 5HT1A receptor by the known agonist, 8-0H-OPAT
(Banasr et aI., 2004, Huang and Herbert, 2005, Soumier et aI., 2010). However,
we found that unlike the 02 receptor, neurogenesis in the rat SGZ is not
mediated by CNTF. In addition, stimulation of the 5HT1A receptor via
intraperitoneal injection of 8-0H-OPAT does not induce neurogenesis in the SVZ
and SGZ of mice or the SVZ of mice or rats. Therefore, 5HT1A receptor
stimulation results in an increase in neurogenesis in the hippocampal formation
of rats at dose of 1 mg/kg/day, which is not mediated by CNTF.

8-0H-DPAT does not increase neurogenesis in the naiVe mice

The initiation of the study in Chapter 2 was due in part to the Santarelli
(2003) paper, which showed increased neurogenesis in the SGZ of 129Sv/Ev
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mice after treatment with 8-0H-OPAT, a 5HT1A agonist, which was diminished in
the 5HT1A receptor knockout mice (Santarelli et aI., 2003). Due to the lack of
neurogenic response in the 5HT1A knockout mice, the 5HT1A receptor seemed
to be solely responsible for the induction of neurogenesis by 8-0H-OPAT in the
SGZ. However, we were not able to replicate the data showing neurogenesis in
the SGZ of 129Sv/Ev mice following 5HT1A receptor stimulation by 8-0H-OPAT
(Santarelli et aI., 2003). In our laboratory, we observed no change in
neurogenesis in the SVZ or SGZ after administration of (R)-(+)-8-0H-OPAT in
either C57BLl6J or 129Sv/Ev mice either acutely (3 days) or chronically (28
days).
So why would we not see increased neurogenesis after administration of
the 5HT1A agonist, 8-0H-OPAT, in mice when the neurogenic response of 8OH-OPAT was seen in wildtype mice and abolished in the 5HT1A knockouts?
There could be a couple of possible reasons for the discrepancy in neurogenic
effects of 8-0H-OPAT between our studies. First, the Santarelli (2003) paper
had used the racemic mixture while we used (R)-(+)-8-0H-OPAT. In humans,
(S)-(-)-8-0H-OPAT binding affinity is similar to that of (R)-(+)-8-0H-OPAT;
however, it is approximately 50% less efficacious or potent than (R)-(+)-8-0HOPAT on the 5HT1A receptor (Cornfield et aI., 1991, Yoshitake and Kehr, 2004).
This would mean that although the two enantiomers bind equally to the receptor,
in the racemic mixture half of the bound receptors produced only 50% activity to
the stimuli resulting in 25% less intrinsic activity than the R-enantiomer alone.
Furthermore, in rats, the racemic mixture is 2-fold less potent than the R-
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enantiomer at reducing dorsal raphe nucleus firing acutely (5 minutes following
injection) (Lejeune et aI., 1997). Presumably, this would also mean that the
racemic mixture could have a 2-fold decrease in the negative feedback produced
by the autoreceptors. However, it is unlikely that this is the reason for the
discrepancy between our two studies.
A second and more likely explanation for the discrepancy could be due to
the behavioral/stress tests performed on in the Santarelli paper. Their goal was
to examine the effects of 5HT1A receptor on depression. Therefore, they were
not working on na·ive mice, but stressed mice. Stress has been shown to affect
production and survival of new neurons (Schoenfeld and Gould, 2011). The
behavioral analysis used in the Santarelli paper includes unpredictable stressor
test, novelty-suppressed feeding test, and cue fear test. Additionally, the
unpredictable stressor test involved changing the environment surrounding the
mice by altering the sawdust bedding, cage tilting, predator sounds, and
modifying to the light cycle. Our studies did not contain any behavior/stress
testing. Additionally, personal correspondence with Benjamin Samuels from
Rene Hen's group, suggested that the increased stress from the behavioral tests
might have lowered the baseline level of neurogenesis in controls. Therefore, 8OH-DPAT stimulation of the 5HT1A receptor could be involved in the restoration
of neurogenesis to basal levels or prevented the decrease in neurogenesis since
behavior testing occurred after administration of 8-0H-DPAT.
Although it is plausible that either the racemic mixture and/or the behavior
testing caused the discrepancy in between the studies in Rene Hen's lab and our
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lab, the discrepancy in neurogenic responses is most likely due to the stressinduced decrease in basal level of neurogenesis observed in the Santarelli
paper. In order to prove this hypothesis, we could look at changes in
neurogenesis triggered by stress from behavioral analysis like what was done in
the Santarelli paper. This could be accomplished using four experimental
groups. The first two groups would not have any behavior testing and would be
administered either saline or 8-0H-DPAT over 4 weeks. The next two groups
would be subjected to behavior tests that cause behavioral/stress tests that
mimic depression in mice with one group receiving saline and the other receiving
8-0H-DPAT. By analyzing the changes in neurogenesis in each of these groups,
we could determine whether 8-0H-DPAT prevents decreases in neurogenesis
caused by conditions that are thought to mimic depression. In addition, if 8-0HDPAT would be given following the induction of depreSSion like behavior in mice,
this would determine if 8-0H-DPAT is protective against reduction in
neurogenesis or can be an anti-depressant by increasing neurogenesis. If 8-0HDPAT were found only to prevent the decline in neurogenesis as a result of
depression instead of increaSing neurogenesis, this would suggest that although
depression decreases neurogenesis, the antidepressant activity is not related to
neurogenesis. This would not be useful in humans as pretreatment for
depression and would only be applicable in people with recurrent depression.
Conversely, if 8-0H-DPAT does indeed increase neurogenesis back to basal
level, it would suggest that neurogenesis plays a role in recovery from
depression. In humans, this would mean that further investigation into drugs that
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would increase neurogenesis could be useful in the treatment of depression.
Therefore it is important to investigate which mechanism is correct for 5HT1A
receptor stimulation so this knowledge can be used to treat depression in human.

Region-selective difference of 8-0H-DPAT effects on neurogenesis in Sprague
Dawley rats

Neurogenesis in the SGZ of rats after stimulation of the 5HT1A receptor
with the racemic mixture of 8-0H-DPAT has been established previously (Banasr
et aL, 2004, Huang and Herbert, 2005, Soumier et aL, 2010). Therefore, we
wanted to test (R)-(+)-8-0H-DPAT in rats as a positive control for bioactivity.
Within seconds of drug administration the typical serotonergic behavior of
weaving head, flat body posture and forepaw treading (Tricklebank et aL, 1985)
was observed in the rats which contrasts to the lack of physical response seen in
mice after 8-0H-DPAT administration. In addition, neurogenesis in the SGZ was
significantly increased after only 3 days of 8-0H-DPAT treatment. This
confirmed that our drug was indeed active and induced neurogenesis in
response to drug treatment that we were able to quantify using unbiased
stereology. However, we did not see any neurogenesis in the SVZ as had been
reported previously at 4 hours after 8-0H-DPAT treatment (Banasr et aL, 2004).
After personal communication with Dr. Annie Daszuta, we found several possible
explanations for the discrepancy in our findings. These differences include
differences in strain, drug, and quantification of neurogenesis. In the Banasr
(2004) paper, they had used the adult Wistar rat and racemic (±)-8-0H-DPAT.
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The differences between the racemic mixture and R-enantiomer were discussed
earlier in Chapter 5. Surprisingly, the quantification for cell proliferation in all
other regions discussed in the Banasr paper was by unbiased stereology with the
exception of in the SVZ where total number of BrdU cells was reported per SVZ
per section with a total of 5 sections counted per animal. Since we used
stereology, a more accurate quantification of neurogenesis, this could be a major
area for discrepancy and might suggest that their conclusion with regards to the
SVZ was incorrect.
Stereology was designed to estimate, for example, the total number of
cells in an anatomically defined area. The balance is in having the appropriate
sampling of a region to encompass an accurate sample of biological variation.
Under sampling and/or oversampling can result in an inaccurate portrayal of the
total number of cells across a region. Therefore, counting every cell present in a
section and averaging the total number of cells per section might be a precise
method, but it is unlikely that it is accurate due to the absence of estimation in the
third dimension. This is due to the inherent biological variation in that cells are
not generally evenly distributed in all three axes or even in the same manner
across animals; therefore, by sampling in the middle of an anatomical region
leads potentially to over estimation and a slight shift toward the edge of the
region could cause under estimation. Thus, in addition to systematic sampling
across the entire area of tissue, the equation used in the total estimation across
the anatomical region takes into account the sampling frequency and tissue
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sampling fraction which minimize the biological variation in order to quantitatively
and accurately estimate the number of cells in the region of tissue analyzed.
Lastly, at 4 hours there would be an acute response to the 5HT1A agonist
to the local 5HT1A receptors, presynaptic receptors located on astroglial cells, in
the SVZ resulting in an increase in neurogenesis (Banasr et aI., 2004). However,
it is possible that by 3 days the 5HT1A autoreceptors, presynaptic receptors on
the projections from the raphe nucleus, have been up regulated in response to
drug administration and their inhibitory function is predominating in the SVZ
(Kinney et aI., 2000). Additionally, the regulation of 5HT1A signaling in the
hippocampal formation is not affected by the autoreceptor which also explains
are response to 8-0H-OPAT in the SGZ but not in the SVZ (Riad et aI., 2001,
Banasr et aI., 2004). Therefore, we conclude that 5HT1A receptor stimulation
can induce neurogenesis in the SGZ, but not in the SVZ at 3 days in rats. In
order to circumvent the negative feedback in the SVZ, lowering the dose or
giving intermittent treatment could potential result in decrease in the negative
feedback. However, the most effective way would be to give pindolol, a
nonselective beta-blocker and partial beta-adrenergic receptor agonist, to
augment the effectiveness of 5HT1A agonist treatment (Kinney et aI., 2000).
Although the mechanism of action of pindolol's augmentation of SSRls and
5HT1A agonists is still in question, it has been shown clinically to bypass the
need for desensitization of the autoreceptors resulting in an almost immediate
clinical effect as contrasting the delayed effectiveness normally seen with SSRI
drug regimens (Kinney et aI., 2000).
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It seems that in rats at least there is region specificity. Although humans
are reported to have neurogenesis in the hippocampal formation, it is difficult to
conclude the possible outcome for humans in light of the species differences
seen between mice and rats. It goes back to the age old question as to which
more closely resembles what occurs in humans. In order to get closer to an
answer for whether 5HT1A induced hippocampal neurogenesis is present in
humans, the next step would be to look at 5HT1A agonists in higher mammals or
move directly to non-human primates which would more accurately predict the
likelihood of effects on neurogenesis in humans. If region specificity is also
found in non-human primates and used to infer the actions of 5HT1A agonists in
human, this would limit treatment to diseases with neuronal loss in the
hippocampal formation such as Alzheimer's disease since there is loss of
neurons in the hippocampal formation among other regions of the brain.
Therefore, treatment of a 5HT1A agonist might improve memory and learning
and decrease aggression in Alzheimer's patients if 5HT1A can elicit a neurogenic
response in the hippocampus (Lai et aI., 2003) .
Although we were not able to increase neurogenesis in the SVZ, the most
active proliferative region of the brain, it is a very important target and potentially
the most effective region to study for neuron replacement. This is due to the
endogenous activity already present in the SVZ such as the ability for new
neurons to migrate great distances under normal circumstances. In order to
develop neuron replacement therapies, continuation of studies which investigate
possible pathways that can be exploited in order to manipulate and/or augment
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neurogenesis in the SVZ is essential. Under the right circumstances, some
diseases states could benefit from increasing neurogenesis in the SVZ such as
stroke, Huntington's, epilepsy, and aging (Curtis et aI., 2007a). Furthermore, it is
important to investigate and understand the differences of these two regions of
the brain such as endogenous regulation by receptors that either stimulate or
inhibit neurogenesis and what types of cells are produced in each region. As
more information is attained on the regulation of neurogenesis, we can apply it to
humans in an effort to control the migration and integration of these new neurons
to better rescue the damage or non-functioning portions of the brain in
neurodegenerative disease.

5HT1A receptors and depression

The 5HT1A autoreceptors are not present in the hippocampal region while
the SVZ is under constant regulation by these autoreceptor unless
desensitization occurs. However, the hippocampal formation is under the control
of the 5HT1 S autoreceptor (Malagie et aI., 2001). The 5HT1A receptor function
and regulation seem to vary depending on the region of interest (Riad et aI.,
2001) which is probably due to the density and localization of the 5HT1 A
receptors. It is hypothesized that the variability in patient responses including
delay in onset of therapeutic effect to the treatment with selective serotonin
reuptake inhibitors in depression is due to the negative feedback of
autoreceptors (Slier et aI., 1998). In a recent study, animals with low and high
amounts of 5HT1A autoreceptors were found to respond differently to stress
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(Richardson-Jones et aI., 2010). The lower the amounts of autoreceptors
present gave better serotonergic tone and responded better to stressors and
SSRI treatment (Richardson-Jones et aI., 2010). Thus, the level of autoreceptors
present could be the main cause of the vast degree of variability in the
effectiveness with anti-depressants drug regimens. Pindolol, primarily known for
being a non-selective beta blocker, is thought to accelerate the therapeutic effect
of antidepressant therapies by inhibition of autoreceptors which reduce firing of
serotonergic neurons resulting in potentiation of the effects of SSRI treatment by
increasing the serotonergic tone of the system (Berney et aI., 2008).
Furthermore, return of autoreceptor function could also explain the development
of resistance after chronic administration of antidepressants.
In general, the depression field has ignored the presence of 5HT1A
receptors on astrocytes and focused on neuronal 5HT1A receptors. Although
5HT1A receptors are in high abundance on glial cells (Whitaker-Azmitia et aI.,
1993), most effects of serotonin are assumed to be as a result of stimulation of
neuronal 5HT1A. In addition, serotonin autoreceptors have attracted attention
over the last decade because of the inhibitory effects on the serotonin pathway
and resulting delay in the therapeutic effect of antidepressants such as SSRls.
The reason for ignoring the glial component of the serotonergic system is
unclear. However, astrocytes provide support for neurons though release of
neurotrophic factors, cytokines, and calcium flux. Therefore, astrocytes should
be considered part of the neuronal network. In neurodegenerative diseases, the
neurons are dead, dying, or not functioning properly and astrocytes are relatively
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unaffected. This puts astrocytes in an advantageous position of being available
and accessible as a tool to promote neurogenesis.

Caveats and future directions for further investigation in neurogenesis

As mentioned earlier in this chapter, stimulation of 5HT1A receptor might
be protective in stress-induced decreases in neurogenesis. In order to
investigate this further, we could use 5HT1A agonist, 8-0H-OPAT, and
antagonist, WAY100135 or (-)-tertatolol (another beta-blocker with 5HT1A
inhibitory activity), to look at the potential for 5HT1A receptor increases in
neurogenesis after a perturbation of the system like a stroke. Strokes located in
different areas of the brain could provide an opportunity to look at regional
differences of 5HT1 A. The murine 5HT1 A receptor might not playa role in
regulating neurogenesis under normal circumstances, but potentially could be
inducible following an insult. However, the drug administration would need to
follow the insult/injury to be clinically relevant which contrasts with the Santarelli
paper where 8-0H-OPAT was given prior to induction of stress. Therefore, it is
possible that 8-0H-OPAT is required to be present before the insult. However, it
could be possible for 5HT1A stimulation following the insult could still result in
protection from subsequent neuronal loss or decreases in neurogenesis.
Additionally, in our hands, a decrease in nNOS seemed to predict
neurogenesis. In fact, nNOS might be a better target for increasing
neurogenesis by using an inhibitor such as L-NAME which has been shown to
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increase neurogenesis in the SVZ of mice (Romero-Grimaldi et aI., 2008). LNAME is a competitive inhibitor of NOS, but unfortunately lacks specificity
between iNOS, nNOS, and eNOS. The lack of specificity comes with a multitude
of side effects such as impairment of memory retrieval/acquisition and blockade
of non-noradrenergic, non-cholinergic nerves leading to erectile dysfunction and
impaired bowel motility (Moore and Handy, 1997). While these side effects do
not preclude the need for further study, they would decrease patient compliance
and potentially prevent FDA approval with a non-specific NOS inhibitor.
Therefore, further study into other receptors that could inhibit nNOS or more
selective nNOS inhibitors would be useful to study in an effort to find additional
drugs that could be used in conjunction with a D2 agonist to promote increases in
neurogenesis and prevent systemic side effects.
Due to the degree of complexity of the 5HT1A pathway, glial 5HT1A
responses are difficult to tease out of the responses seen with 5HT1A agonist. It
seems likely that the lack of neurogenic effects in the SVZ after 8-0H-DPAT
systemic administration could be attributable to inhibition by 5HT1A
autoreceptors. This could be confirmed by knocking out the autoreceptors by
de nervation of the raphe nuclei using the serotonergic neurotoxin, 5,7dihydroxytryptamine which alone has been shown to increase neurogenesis. In
addition by varying the degree of denervation, one could potentially see a dose
dependent increase in neurogenesis. In our studies, we saw a region and
species specificity to the activity in response to the 5HT1A agonist, 8-0H-DPAT.
There are also marked differences in the responses between mice and rats
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which were described in Chapter 2. Therefore, further research is needed in
order to tease out the specific mechanism of action of the 5HT1A receptor in
specific regions of the brain. However, one must question the validity of studying
the 5HT1A receptor in rodents when there is such a wide range in responses to
stimulation. Although the 5HT1A receptor has 89% homology between rats and
humans and 86% homology between mice and humans, there seems to be
drastic differences in the function in difference species. The lack of serotonergic
syndrome in mice given up to 10 times the normal dose of 8-0H-OPAT given to
rats leads me to believe that the murine 5HT1A receptor does not have the same
biological function as in humans and rats. Since both rats and humans can
exhibit serotonergic syndrome in response to serotonin, rats seem to be the
better choice for further study into the function of the 5HT1 A receptor before
studying this paradigm in non-human primates or humans.

What would I have done differently in Chapter 2?

One of the biggest problems with Chapter 2 is the lack of a biological
effect in the mouse. In order to understand the activity of 8-0H-OPAT activity in
the mouse, it would have been nice to have added a couple of experiments that
looked at the bioactivity of 8-0H-OPAT on mice. First, our hypothesis was that
the decrease in cAMP following 5HT1A stimulation would cause an increase in
CNTF. However, we never measured cAMP. If we had measured cAMP levels
we might have seen, for instance, that there was no change in cAMP. Then we
could have either adjusted the dosage or found another drug to test for changes
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in cAMP before doing so much work looking at mRNA and neurogenesis
analysis. In addition, mild hypothermia was reported in mice following treatment
with 8-0H-DPAT. It would have been relatively simple to test the temperature of
the animals periodically throughout the study for changes in the basal body
temperature. A change would indicate bioactivity. Lastly, I could have added
another experimental group that combined 8-0H-DPAT with a 5HT1A antagonist
to determine if the auto receptors were causing the lack of effect in mice.

Summary of findings from Chapter 3 and 4

In Chapter 3 we found that the absence of ADAM21 protein did not result
in a function phenotype measured by two locomotors tests, BMS and beam walk,
and two thermal nociception tests, Hargreaves and tail flick. Histologically, we
found no significant difference between genotypes in spared white matter, GFAP
immunostaining, or CGRP immunostaining. The neutral phenotype was thought
to be a result of compensation by another zinc metalloproteinase; however, we
found no evidence of compensation on the mRNA level for the absence of
ADAM21. Interestingly, we found a massive decrease in several genes which
have been associated with inflammation, i.e., ADAM8, ADAM33, MMP12, and
TNFo. These changes lead us to believe that ADAM21 has a regulatory role in
the inflammatory gene response following spinal cord injury. Thus far, these
changes in mRNA have not given a functional phenotype, but become the basis
for further research into the role of ADAM21.
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Hypothesis for potential role of ADAM21 in pain development following spinal
cord injury

As mentioned in Chapter 3 and 4, robust ADAM21 immunostaining was
found in highly plastic areas of the brains (Yang et aI., 2005). In addition, it is
predicted to have a catalytically active zinc metalloproteinase site which
pharmacologically makes it a great target for inhibition by a small molecule. Our
original hypothesis was based off the ADAM21 immunostaining in growing axons
and presence in radial glial lineage cells. We wanted to investigate the possibility
that ADAM21 was involved in sprouting after spinal cord injury. Upon
immunostaining for ADAM21 in the spinal cord it was found to be localized in
laminae I and II of the dorsal horn and in the ependymal cells surrounding the
central canal. The staining in the dorsal horn was punctated and occasionally
resembled fibers. Since nociceptive fibers (C and Ao fibers) correspond to the
location of ADAM21, we chose to investigate the role of ADAM21 in the pain
response after spinal cord injury using ADAM21-deficient mice. Conversely, we
now believe that the ADAM21 immunostaining is an artifact and does not
resemble the true localization of ADAM21 in the spinal cord due to the lack of colabeling of ADAM21 and l3-galactosidase immunostaining. As the basis for our
original hypothesis turned out to be false, it makes sense that we did not see
changes in sprouting of CGRP in the dorsal horn or changes in GFAP since this
is not the region or cell type the ADAM21 protein is located.
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ADAM21 deletion and spinal cord injury

A cluster of genes known to be linked with inflammation was greatly
increased in wildtype, but considerably reduced in their response to injury in the
ADAM21-deficient mice (i.e., ADAM8, ADAM12, ADAM33, MMP12, and TNFa).
Increases in inflammation would presumably cause increases in pain and
decrease in locomotor function. Likewise, decreases in inflammation should
produce decreases in pain and improved locomotor function, but this was not the
case with ADAM21 deficient mice. ADAM21 lacked a functionally significant
difference in pain development after spinal cord injury as we found no changes in
thermal nociception measured by Hargreaves and tail flick tests following spinal
cord injury. In addition, ADAM21-deficient mice responded similarly to the spinal
cord injury as the wildtype littermates in all parameters tested.
A possible explanation for the absence of a function phenotype is that the
changes in mRNA as a result of the lack of ADAM21 protein did not translate into
a reduction in inflammation. Until we are able to look at the immunological
response in the ADAM21-deficient mice, this conclusion is purely speculative. As
discussed in Chapter 4, ADAMs and other metalloproteinases have been shown
to overlapping physiological functions {Horiuchi, 2005 #2187, but there was no
evidence of compensation by another zinc metalloproteinase. Yet other proteins
could compensate or regulate the changes resulting from a lack of ADAM21 such
as TIMPs, a group of endogenous metalloproteinase regulators. Although there
were changes in 3 of the 4 TIMPs following spinal cord injury, there was not a
significant difference in the changes in TIMPs between genotypes. The
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consistent inhibitory tone of the system could account for the lack of a phenotype
if the changes in metalloprotease were inhibited to the same extent in both
wildtype and ADAM21-deficient mice. For instance, TIMP1 could mitigate the
different changes in metalloproteinases resulting in the neutral outcome that was
observed. In order to confirm this is the case, a double knockout of TIMP1 (or
other TIMPs) and ADAM21 should be compared. However, combinations of
small changes in TIMPs and metalloproteinases could account for no lack of
compensatory mechanism in ADAM21 deficient mice.
Another possibility is the fact that we are looking at mRNA levels at 7 and
14 days post injury. It is possible that an increase/decrease in mRNA does not
translate into an increase/decrease in protein levels/activity. Therefore, the
changes in mRNA could be transient and any affect as a result of these acute
changes could be diminished over the 6 weeks. In addition, we only looked at
these two early time points which could not be giving us a full picture as to what
is going on in the system.
Spinal cord injury resulted in numerous changes in metalloproteinase
activity, but none of these changes resulted in a functional phenotype. Due to
the complexity of the regulatory mechanisms of metalloproteinases, it is plausible
that other proteins not included our array could compensate the lack of a
phenotype such as feedback or feed forward loops like seen with ADAM8,
TNFa, and TNFR1. In addition, regulation of both beneficial and destructive
metalloproteinases and/or TIMPs could explain the neutral phenotype. An
example of this would be the feedback loop of ADAM8 and TNFa that was
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discussed in Chapter 4 (Bartsch et aI., 2010). Although there is no evidence of
compensation of ADAM21, the complexity of the regulation of the
metalloproteinases by not only each other, but also TIMPs and other proteins
make finding a definitive compensatory mechanism challenging.

Caveats pertaining to ADAM21-deficient mouse

During the course of the array portion of the study, it was discovered that
exon 1 of ADAM21 was not present in the spinal cord. This was not unexpected
since it was reported that exon 1 of ADAM21 in the testis was only present in
germ cells (Yi et aI., 2010). After obtaining an assay for exon2, we found
expression of ADAM21 in both wild type and ADAM21-deficient mice. However,
under further investigation of the mRNA from ADAM21-deficient mice, we found
that the insertion site of the LacZ cassette was in the middle of the
metalloproteinase domain effectively eliminating the potential for
metalloproteinase activity. We also found that starting at the beginning of the
disintegrin domain, mRNA transcription resumed to include the rest of the Cterminal portion of the ADAM21 transcript. Upon further investigate a theoretical
promoter region followed by a putative start codon was found downstream of the
metalloproteinase catalytic site. However, this is highly speculative until we are
able to determine if this truncated transcript is translated into protein.
Unfortunately, additional ADAM21-deficient mice were not available to confirm
presence of a truncated ADAM21 protein. Additionally, our antibody for ADAM21
shows similar immunoreactivity in wildtype and ADAM21-deficient mice. This
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means either that our antibody is not specific or it is detecting a truncated
ADAM21 protein. Lastly,

~-galactosidase

immunostaining revealed a different

expression pattern than was seen with the ADAM21 antibody. This probably
means that the ADAM21 antibody is not specific and would explain why our
original hypothesis failed-it was based off false information. Therefore, the
exact type of genetically modified ADAM21 we have obtained is still in question.
We have two options available: a metalloproteinase-null ADAM21 and the
function of the other domains remain intact or we could have an ADAM21deficient mouse that has truncated ADAM21 mRNA that lacks the ability to be
translated into protein. We plan to investigate further these two possibilities by
using another antibody for ADAM21 which recognizes the metalloproteinase
domain which will be validated by

~-galactosidase

antibody has the same immunostaining as the

immunostaining. If this

~-galactosidase

antibody then the

ADAM21 antibody that targets the C-terminus, PSGPKETKASSPG, is not
specific to ADAM21. Of note, BLAST analysis of this 13 amino acid sequence
produced only one exact match, ADAM21, but included partial matches to 140
other mouse proteins. If, however, the pattern of staining with the new ADAM21
antibody matches our C-terminus ADAM21 antibody, then there could be some
alterations in the expression pattern of

~-gal

such as different regulation,

transport, or processing. Lastly, if the truncated protein is present, this would
suggest that the changes in inflammatory gene were a result of the lack of
metalloproteinase activity of ADAM21. Whereas, a knockout of the entire protein
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does not allow one to discern which domain is responsible for the gene changes
that occurred after spinal cord injury.

Future directions

The data from the ADAM21 deficient mice suggests that ADAM21 does
not playa role in pain development or influence the recovery of locomotor or fine
motor control following spinal cord injury. In apparent contradiction, ADAM21
could potentially be involved in the inflammatory response following spinal cord
injury. Massive changes in metalloproteinases and TNFa point to ADAM21
having a regulatory role following spinal cord injury. Although there were other
changes in mRNA levels of other metalloproteinase, the magnitude of change
seen in this cluster of inflammatory genes points to a more direct relationship
between them and ADAM21. Further validation is still needed. Validation of
these results could be accomplished by the following techniques: western blot,
ELISA, or immunostaining for the genes of interest. In addition, following up with
the use of CD45 and CD68 immunostaining (microglia and
monocytes/macrophages, respectively) in the spinal cord tissue of ADAM21deficient mice as an indicator of the degree of inflammation would give us a
better ideas as to the degree of inflammation in these mice compared with
wildtype littermates. If ADAM21 is indeed a master regulator of inflammation
following spinal cord injury, this could open up a new avenue for manipulation of
inflammatory processes by blocking ADAM21 activity with a small molecule could
potentially provide an avenue for reduction of inflammation. First, the pro-
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inflammatory activity of ADAM21 would need to be narrowed down to the domain
responsible. Although this would need further investigation to confirm, more than
likely the metalloproteinase domain is the primary domain responsible for
changes seen in the inflammatory genes upon deletion of ADAM21.
Confirmation could be done by point mutations of the catalytic site of ADAM21
resulting in a metalloproteinase dead protein.
Although there are metalloproteinase inhibitors, there is not an ADAM21
metalloproteinase specific inhibitor to date. The use of broad-spectrum
metalloproteinase inhibitors would inhibit large groups of metalloproteinases and
is not desirable. However, continued effort has been put into design of inhibitors
of specific metalloproteinases although selectivity of such an inhibitor is a great
obstacle due to the high degree of homology of the catalytic site of zinc
metalloproteinases (Fisher and Mobashery, 2006, Corbitt et aI., 2007, Jacobsen
et aL, 2010). Non -specific metalloproteinase inhibition results in detrimental side
effects such as MMP-induced musculoskeletal syndrome which can cause
muscle stiffness, loss of range of motion in large joints, joint swelling, and soft
tissue pain as seen in rats (Renkiewicz et aL, 2003) and humans (Coussens et
aL, 2002, Krzeski et aL, 2007). Therefore, specific inhibitors would reduce side
effects like those mentioned above. The most successful method for increased
specificity in the development of metalloproteinases has been accomplished
using bioinformatics to model the catalytic site. The catalytic site contain 6
recognition "pockets" around the catalytic zinc and the distance between these
pockets vary among the different metalloproteinases (Dorman et aL, 2010). By
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utilizing this difference and the computing power of computers, potential selective
small molecules can be found and tested for selectivity and bioavailability.
Alternatively, small peptide based drugs could be designed to bind to more
specific regions around the catalytic site to block access.
The question remains whether we could reduce the chronic inflammation
after spinal cord injury which has been shown to be detrimental consequences in
the long-term for spinal cord injury patients. A specific inhibitor of ADAM21
metalloproteinase would have many hurdles to overcome before it could be
brought to the clinic. Once a suitable candidate is identified, the timing of when
to begin treatment of the inhibitor and the duration of treatment would need to be
determined. Some inflammatory processes are beneficial and the exact time
when beneficial inflammation turns detrimental is still under investigation
(Popovich and Jones, 2003, Crutcher et aI., 2006, Sandhir et aI., 2011). Is it
required for the rest of the patient's life to keep the chronic inflammation at bay?
These question still need to be answered and I believe it is important to work to
find inhibitors specific to different metalloproteinases than could be used not only
in spinal cord injury but also asthma, cancer, periodontal disease and many more
diseases as the metalloproteinases are involved in a vast range of diseases.

What would I have done differently in the Chapter 3 and 4?

If I could change the order in which I looked at the role of ADAM21 we
might have more answers than questions at this point. Initially upon receiving the
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ADAM21-deficient mice, I should have confirmed by qPCR that ADAM21 mRNA
was not present. This way I would have been able to figure out whether or not
the truncated transcript of ADAM21 is translated into a truncated protein or
degraded. This would have allowed me the time to explore what type of
genetically modified mouse we had before spending countless hours doing a
spinal cord injury study which left many more questions than it answered due to
the current uncertainty of the mouse strain. In the process of investigating this
mouse strain, I would have run a western to confirm protein sizes and the
absence or presence of a truncated protein and done

~-galactosidase

immunostaining from the start to look which cells produced ADAM21. This would
have led to the inconsistency in the

~-galactosidase

and ADAM21 staining. All of

which could have been confirmed before years of work went in to a mouse that
mayor may not be a true knockout. Of course looking back, it would have been
nice to have done the comprehensive array following spinal cord injury prior to
the 6 week behavior study on pain and plasticity in order to formulate a better
experiment that could have better answered what role ADAM21 has after a spinal
cord injury.
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